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Department of Physical Therapy and Human Movement Sciences &  
Robert H. Lurie Comprehensive Cancer Center  
Feinberg School of Medicine, Northwestern University 
 
The Department of Physical Therapy and Human Movement Sciences (PTHMS) and Robert H. Lurie 
Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, are inviting 
applications for a full-time, tenure eligible faculty position in the area of oncology rehabilitation. Primary 
responsibilities will include developing a strong research program with strong multidisciplinary links to the 
Lurie Cancer Center. Furthermore the candidate will be involved in a Lymphatic and Integumentary 
Dysfunction related coursework in the Doctor of Physical Therapy (DPT) curriculum. The position also 
includes PhD and DPT student advising, service on departmental committees, and practice opportunities in 
clinical oncology rehabilitation. Depending on the experience and background of the applicant, this position 
is being offered at the assistant or associate professor level. Salary is commensurate with experience. 
Generous start-up package will be offered. Ideal applicants will hold the credentials of PT, PhD; have post-
doctoral experience; have a record in obtaining federal training/research funding and expertise in the 
management of lymphedema.  
 
PTHMS and the Lurie Cancer Center are a part of the vibrant educational and cultural community of 
Northwestern University. Both are located on the Chicago campus of Northwestern University, between 
Lake Michigan and North Michigan Avenue. The Robert H. Lurie Cancer Center is a National Cancer 
Institute-designated “Comprehensive” center dedicated to the highest standards of cancer research, patient 
care, education, and community outreach. Collaborations also exist with the Departments of Biomedical, 
Mechanical Engineering, Physical Medicine & Rehabilitation, Neurology, Physiology, Orthopedics, and 
Neurological Surgery. The successful applicant is expected to continue to build on existing and new 
collaborations. PTHMS and Lurie Cancer Center faculty members participate in PhD student training 
programs through the Northwestern University Interdepartmental Biological Sciences Graduate Program, 
Interdepartmental Neuroscience Program, and a joint DPT-PhD (Engineering) program. For more 
information please visit: http://www.cancer.northwestern.edu/home/index.cfm and 
http://www.feinberg.northwestern.edu/nupthms.  
 
Northwestern University is an Equal Opportunity, Affirmative Action Employer of all protected classes, 
including veterans and individuals with disabilities. Women and minorities are encouraged to apply. Hiring 
is contingent upon eligibility to work in the United States.  
 
Applications will be considered until position is filled with an anticipated start date of August 1, 2015.     
Interested applicants should send a letter of application, statement of research goals and teaching philosophy, 
curriculum vitae, and the names and addresses of three professional references to:  
 
Ms. Erin Neal 
Search Committee Coordinator 
Department of Physical Therapy & Human Movement Sciences 
645 N. Michigan Ave, Suite # 1100 
Chicago, IL 60611 
Email: e-neal@northwestern.edu 
Phone: 312.503.3163 
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President’s Perspective
Lisa VanHoose, PT, PhD
President of the Oncology Section;
Department Chairperson and Associate Professor, Hampton University, Hampton, VA
Mahatma Gandhi stated that “the best way to find yourself 
is to lose yourself in the service of others.” As you treat your 
patients today and tomorrow, take a moment and ask if being a 
physical therapist (PT) or physical therapist assistant (PTA) is 
a service or a job for you. Your self-assessment will determine 
your role as the profession and the Section move forward with 
education, policy, research, and outreach initiatives. Service and 
employment are not synonymous. A job or employment will 
mandate that you continue with the status quo. You will treat 
your patients, document, and read just enough research to select 
a functional outcome measure and tool for billing. A job is just 
that—meeting the employment requirements so that one may 
receive money or compensation. Service is more dynamic and 
includes passion, courage, and innovation. The PT or PTA who 
views the profession as a service contemplates the needs of the 
field and the public in the future. He or she seeks out new knowl-
edge to address those needs. He or she has the courage to imple-
ment strategies to address the needs. Service requires that we be 
an active part of the solution to address the movement needs of 
our communities, thereby transforming society.
I strongly believe that an intersection exists between service 
and research. Many times, data about the needs of a community 
or the generation of ideas or possibilities about an intervention 
kindles a flame for a new program, technique, or care delivery 
strategy. We also see the opposite, where passion about commu-
nity needs drives the next research question and project. Research 
grants focus on societal impact and innovation. We are encour-
aged to develop projects across institutions and state lines. Multi-
site research studies have been utilized for years to improve 
recruitment and the impact of the studies. We have been able to 
freely enter into these courageous and creative ventures, because 
we were not restricted by licensing requirements and practice 
acts. We are excited to see this spirit of innovation and possibili-
ties moving into the delivery of physical therapy services.
The Federation of State Boards of Physical Therapy (FSBPT) 
began conversations regarding the need for interstate licensure 
compacts in 2010. The FSBPT had the foresight to identify that 
our licensing processes would be a barrier to accessing physi-
cal therapy care. In 2014, the FSBPT Compact Advisory Team 
determined that interstate compacts are needed and feasible. The 
interstate licensure compact would allow for two or more states 
to agree on a “privilege to practice” model in remote states. The 
current model recommendation would allow a PT or PTA to hold 
an unrestricted license in a primary state and then he/she would 
notify remote states, participating in the licensure compacts, of 
practice. The notification, and possibly a fee, would allow for 
“privilege to practice” in remote states. This opportunity would 
have immediate impact for many of us providing oncology reha-
bilitation care. Cancer care is often a shared care model between 
academic medical centers, specialized medical care centers, and 
community health care centers. Often, our patients travel across 
state lines for care due to medical needs or personal factors. The 
proposed interstate licensure compacts would allow us to provide 
on-site care without the additional burdens of state licensing. 
Even more exciting is that interstate licensure compacts would 
remove barriers to providing telehealth and telerehabilitation. 
It will allow opportunities for many of us to provide essential 
services to those who need us most, in rural and underserved 
communities. I do believe that each and every one of us will 
answer the call to provide physical therapy care with a creative, 
passionate, and courageous spirit that can only be described as a 
service and not a job. As we serve others, I look forward to each 
of us finding ourselves. 
Move forward,
Lisa 
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Editor’s Message 
Lucinda (Cindy) Pfalzer, PT, PhD, FACSM, FAPTA
Editor of Rehabilitation Oncology and Professor (Emerita), Physical Therapy Department, 
University of Michigan-Flint, Flint, MI
The lazy days of summer—do we remember when we 
thought summer would last forever; but change is inevitable. 
There is major news from the Section regarding publication of 
the Journal—we have a new publisher beginning January 2016. 
Before I get to what this means for the Section and Journal, let me 
take a moment to acknowledge the integral role the Orthopaedic 
Section has played for our Journal for many years. Sharon Klinski 
has been our publisher since 1997 and a large part of the credit for 
the quality of the Journal is hers. Thank you Sharon for of all of 
your years of dedicated service to the Journal. We appreciate all 
of the work that has gone into making the Journal a success.  The 
decision to change publishers was to bring the Journal into the 
multi-media age we now live in.  The Journal’s new publisher is 
Wolters Kluwer.  This publisher will be able to provide improved 
access to the Journal in e-reader format, an iPhone app, a search-
able portal for members to download individual pdfs of articles 
all the way back to the first published issue of the Journal, 
an improved webpage and web content for the Journal, and 
lastly, increase the reach of the Journal with indexing in OVID. 
The Journal is now available electronically through ProQuest, 
EBSCO Rehabilitation, Allen Press, and CINAHL. There are 
more benefits the members don’t see; but are important for the 
quality and work of the Journal such as the electronic manuscript 
management system for the authors, reviewers, Associate Editors, 
and Editor. I look forward to hearing your feedback next year 
specifically regarding the new electronic features of the Journal 
as we transition the Journal to multi-media.
Back to this issue of the Journal, it was a busy first half of 
the year with two issues jam packed with research that continues 
the focus on evidence for practice.  This issue has 4 systematic 
reviews from the Section’s EDGE task forces for head and neck 
cancer, breast cancer, and prostate cancer.  You have an issue full 
of information that translates to practice by addressing your needs 
to select better outcome measures to improve the examination 
and reporting of the care you provide.  The Research Round-up 
(available via ePub at oncologypt.org/publications/rehabilitation-
oncology-journal) column reports on the Cancer Rehabilitation 
Symposium that was hosted by the Rehabilitation Medicine 
Department (RMD) of the National Institutes of Health (NIH) 
Clinical Center and was co-sponsored by the National Cancer 
Institute and the National Center for Medical Rehabilitation 
Research this past June in Bethesda, Maryland.  There was lively 
discussion, and we look forward to the publication of the work-
ing papers and research agenda.  Please take a moment to read 
about this important initiative.  As always, we are open to your 
feedback.
Celebrate LivingOncology Section
American Physical Therapy Association
2015 ONCOLOGY SECTION SLATE OF CANDIDATES
Vice President
Amy Litterini, PT, DPT
Secretary
Mary Fisher, PT, PhD, CLT          Emily Hemingway, PT, DPT, ATC
Nominating Committee Member
Nancy Paddison, PTA, BA, CLT-LANA          Laura Sheridan, PT, DPT, CLT          Kathy Tasillo, PT, DPT
Go to www.oncologypt.org to View Each Candidate’s Biography Form
Erratum. The authors wish to correct an error in their article 
“Recommendations for patient-reported outcome measures 
for head and neck cancer-related shoulder dysfunction: A 
systematic review” volume 32, issue 3, 2014, p. 10. The state-
ment on the scoring of the NDII should instead read “A lower 
score indicates greater impairment.41,46”  The authors had this 
reversed and we (manuscript reviewers and I) did not catch 
it.  It was published as  “A higher score...” and it should read 
“A lower score...”
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EDGE Task Force on Head and Neck Cancer Outcomes 
A Systematic Review of Outcome Measures for 
Temporomandibular-related Dysfunction
Mary Lou Galantino, PT, MS, PhD, MSCE1; Melissa M. Eden, PT, DPT, OCS2;  
Bryan A. Spinelli, PT, MS, OCS, CLT-LANA3; Ann Marie Flores, PT, PhD, CLT4
1Professor of Physical Therapy, School of Health Sciences, Stockton University, Galloway, NJ
2Assistant Professor of Physical Therapy, Mayo Clinic, Phoenix, AZ
3Rhode Island Hospital, Rehabilitation Services, Providence, RI
4Assistant Professor & Director, Center for Cancer Survivorship Studies, Department of Physical Therapy,  
Movement and Rehabilitation Sciences, Northeastern University, Boston, MA
ABSTRACT
Background:  Patients with head and neck cancer (HNC) often 
experience significant postoperative limitations in temporoman-
dibular joint (TMJ) function, facial pain, reduced nutritional 
intake, speech impairments, and compromised activities of daily 
living due to side effects of cancer treatment. Physical therapists 
treating these individuals must use valid and reliable patient-
reported outcome measures to quantify change related to physi-
cal therapy intervention for the TMJ. Purpose: As part of the 
activities of the Oncology Section EDGE Task Force on Head and 
Neck Cancer Outcomes, we report evidence-based recommenda-
tions for patient-reported outcome measures for individuals with 
HNC-related temporomandibular dysfunction (TMD). Methods: 
A systematic literature review of TMD-related patient-reported 
outcome measures that are clinically feasible and relevant to 
the HNC patient population was conducted using the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) model. Recommendations are based on the quality 
of psychometric properties, clinical utility, and previous use 
in HNC-related research. Twenty-two outcome measures were 
selected for review; 4 received a rating of 3, “recommended” for 
use in the HNC population. Conclusions: A variety of outcome 
measures have been reported in the literature for individuals with 
HNC-related TMD. Four measures, the Graded Chronic Pain 
Scale, 8 and 20-item Jaw Functional Limitation Scale and TMD 
Pain Screener, are recommended for clinical use by the research-
ers on this task force although it is important to note psychomet-
ric properties specific to the HNC population are lacking. 
Systematic Review Registration Number: PROSPERO 
CRD42013004898
Key Words: temporomandibular, impairment, outcome measure, 
head and neck cancer 
INTRODUCTION
The incidence of head and neck cancer (HNC) has remained 
stable over the past decade due to improvements in the medical 
management of the disease, and a 5-year relative survival rate of 
60% to 65%.1,2 Treatment for HNC may include a combination of 
surgery, radiation, and/or chemotherapy. As of 2012, there were 
364,000 HNC survivors in the United States, many of whom 
are dealing with the long-term sequelae of HNC treatment.1 
The location and nature of the medical management of HNC 
places survivors at risk for experiencing temporomandibular 
joint (TMJ)-related impairments and disability, which can lead to 
temporomandibular joint dysfunction (TMD).2-4 
Temporomandibular joint dysfunction is defined as “func-
tional disturbances of the masticatory system.”5 Changes in TMJ, 
occlusion, ligamentous, or soft tissue structures, or the muscles 
of mastication eventually can result in TMD. The TMJ and masti-
catory system is complex and requires a comprehensive under-
standing of the anatomy and physiology of the arthrokinematics, 
musculoskeletal, and neurological components in order to treat 
TMD. Trismus, restricted mouth or jaw opening, is a form of 
TMD that affects 10% to 50% of those with HNC.4,6,7 
Radiation therapy for nasopharyngeal, base of tongue, sali-
vary gland, maxillary, or mandibular often affect the TMJ and 
associated musculature including the pterygoid and the masseter 
muscles.4,8 Loss of TMJ function and range of motion from radia-
tion therapy appear to be related to fibrotic changes to TMJ soft 
tissue, including the muscles of mastication.8,9 The HNC postop-
erative precautions resulting in changes to movement of the TMJ 
may also compound emotional aspects and guarding of the TMJ 
causing a vicious cycle of reduced movement, pain, and altered 
function.8 Trismus in patients with HNC can have serious health 
implications, including reduced nutrition due to impaired masti-
cation, difficulty speaking, impaired self-image, ineffective oral 
hygiene, and compromised assessments for cancer surveillance.6,8 
Address correspondence to: Mary Lou Galantino, PT, 
MS, PhD, MSCE, School of Health Sciences, Stockton 
University, 101 Vera King Farris Drive, Galloway, NJ 08025 
(MaryLou.Galantino@stockton.edu).
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In persons who receive radiation to the head and neck, trismus is 
often observed in conjunction with dysphagia.10 
A systematic review published in 2014 highlights the 
following 12 core domains and symptoms most affected in 
HNC survivors: swallowing, oral pain, skin changes, dry mouth, 
dental health, opening mouth/trismus, taste, excess/thick mucus/
saliva, shoulder disability/motion, voice/hoarseness, and social 
and functional domains.11 It has been reported that individuals 
with HNC have a lower quality of life (QOL) than age-matched 
controls and in many cases a lower QOL than individuals with 
other common cancers.12 However, little research has been 
conducted studying TMD in people with HNC that fall within 
the scope of physical therapy practice. The few studies related to 
TMD in HNC have suggested that pain and restricted motion are 
problems experienced by some HNC survivors.3,13-15 
Physical therapy assessment must include outcome measures 
of physical function, which may include patient-reported outcome 
measures (PROs). Despite the risk of TMJ impairments and 
disability in the setting of HNC, physical therapists have very 
few HNC-specific PROs from which to choose. In fact, a panel 
of HNC experts were unable to recommend a PRO specific to 
TMD or trismus in the “outcomes toolbox for head and neck 
cancer research,” a series of PROs addressing 18 main areas of 
concern in the HNC population. The authors only offer an objec-
tive measurement for trismus—the interincisal distance.16 
When selecting an outcome measure in practice, a physical 
therapist must first consider the ability to interpret the test score 
in the population of interest. This requires that the psychometric 
properties of the outcome measure, such as reliability, valid-
ity, sensitivity, specificity, and the ability to detect change, are 
available in a population similar to the one of interest. Clinical 
utility, the ease of use, and accessibility of needed resources to 
administer the measure, are also important factors to consider 
when choosing an outcome measure. The Evaluation Database to 
Guide Effectiveness (EDGE) initiative by the American Physical 
Therapy Association (APTA) is currently identifying core sets of 
recommended tests and measures to be used within certain patient 
populations and diagnoses.17 The Oncology Section of the APTA 
has established task forces for breast, prostate, lung, urogyneco-
logic, and head and neck cancers. The purpose of this systematic 
review is to identify and provide recommendations of clinically 
feasible and relevant PROs that address pain and function for use 
in patients with HNC presenting with TMD.
DATA & METHODS
This systematic review is registered on PROSPERO 
(CRD42013004898). The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) model was 
utilized for this systematic review (Figure 1, Appendix 1).18 The 
appendices for this article can be accessed via ePub at www.
oncologypt.org
Two investigators (MLG and MME) independently completed 
the literature search in April 2014 using Ovid Medline. PubMed, 
PEDro, EBSCO Host, PsycInfo, and Cochrane Databases were 
subsequently explored using similar search strategies and terms 
(Figure 2). The literature search was limited to human subjects, 
availability of an abstract for screening, and publication in the 
English language. Because little research on this subject is avail-
able, we did not exclude studies based on publication date or level 
of evidence. Once duplicates were removed, 1068 total articles 
remained for review (Figure 1). 
Article titles and abstracts were reviewed, yielding 38 identi-
fied PROs. Of these, 22 were chosen for inclusion in the system-
atic review (Figure 1). To be included in the review, outcome 
measures had to be clinically feasible and patient-reported. 
Patient-reported outcome measures addressing health related 
QOL were excluded unless they were specifically developed 
for the HNC population. In addition, questionnaires assess-
ing nonspecific impairment level constructs (ie, visual analog 
scale) and other joints/regions not specific to the TMJ region (ie, 
Dental Discomfort Questionnaire, 10-item cervical questionnaire, 
Sinonasal Assessment Questionnaire) were excluded. Outcomes 
specific to HNC that did not contain items related to TMJ func-
tion (ie, Cancer Problems in Living Scale, FACT H&N) were 
also excluded. 
The 22 outcomes were divided between the two investiga-
tors for analysis. Relevant studies and full-text articles for each 
measure were retrieved to assess the clinical utility, psychometric 
properties, and relevance of the PROs to the HNC population. 
Clinical utility was based upon cost, ease of use and scoring, 
equipment requirements, and availability of normative data. 
Ease of use, based on responder burden, and ease of scoring 
were characterized as easy, moderate, or difficult. The primary 
reviewer completed the Head and Neck Cancer EDGE Task 
 24 
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Figure 1. PRISMA flow diagram for systematic review.
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Force Outcome Measure Rating Form (Appendix 2) for each of 
the assigned measures. Recommendations for each PRO were 
provided using a rating scale of 1 to 4, where a rating of 1 is not 
recommended and a rating of 4 is highly recommended (Table 
1). The risk of bias at the study level was not considered when 
completing the Rating Form, however, we attempted to decrease 
the level of reporting errors through a review by the second inves-
tigator. In the case of disagreement between the two investigators, 
the rating in question would be brought to the entire HNC EDGE 
Task Force for consensus. 
RESULTS
After a systematic review of the HNC literature, 22 
TMD-related patient-reported outcome measures were identified 
for inclusion in this review. The HNC EDGE Task Force recom-
mendations for TMD outcome measures can be found in Table 2. 
“Highly Recommended” TMD Outcomes Measures
Of the 22 measures reviewed, no outcome measures merited 
the maximum score of 4 and the rating “Highly Recommended.” 
The investigators were unable to find a PRO specific to TMD, 
which was previously utilized in the HNC research and demon-
strates strong psychometric properties and clinical utility.
“Recommended” TMD Outcomes Measures
Four outcome measures received a score of 3, 
“Recommended.” These outcome measures include the 8-item 
and 20-item Jaw Functional Limitation Scale (JFLS-8, JFLS-
20), the TMD Pain Screener, and the Graded Chronic Pain Scale 
(GCPS). Although no published evidence of the psychometric 
properties in the HNC population were found, these measures 
have demonstrated good psychometric properties and clinical 
utility in other patient populations (Tables 3 and 4). 
Table 1. Head and Neck Cancer Rating Scale
4 Highly Recommend Highly recommended; the outcome has good psychometric properties and good clinical utility; the measure has been used in research on individuals with or post head and neck cancer.
3 Recommend Recommended; the outcome measure has good psychometric properties and good clinical utility; no published evidence that the measure has been applied to research on individuals with or post head and neck cancer.
2A Unable to Recommend  at This Time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure; 
the measure has been applied to research on individuals with or post head and neck cancer.
2B Unable to Recommend  at This Time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure; 
no published evidence that the measure has been applied to research on individuals with or post head and neck cancer.
1 Do Not Recommend Poor psychometric and/or poor clinical utility (time, equipment, cost, etc)
25
Figure 2. Terms for Online Database Search 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Terms for online database search. Literature search limits included the following: human subjects, English, full abstracts 
available.
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The JFLS-20 is a 20-item measure derived through expert 
consensus and subsequently validated using Rasch method-
ologies in a sample of patients with TMD, primary Sjogren 
syndrome, burning mouth syndrome, skeletal malocclusion, and 
healthy controls.19 It includes 3 subscales (mastication, vertical 
jaw mobility, and verbal and emotional expression) and a global 
scale of functional limitation of the jaw. The 8-item global scale 
of functional limitation of the jaw is known as the JFLS-8. The 
JFLS-8 and the JFLS-20 can both be appropriately utilized to 
measure TMD dysfunction in clinical and research settings.19,20 
Both scales require the patient to rank their level of difficulty on 
an 11-point Likert scale, where zero suggests “no limitation” and 
a response of 10 suggests “severe limitation.” The recall period 
is one month. The total score is calculated by summing the indi-
vidual item scores, with a higher score indicating greater limita-
tion.19 The JFLS-20 score can range from 0-200 and the JFLS-8 
score can range from 0-80. 
Internal consistency (Cronbach’s alpha) for the JLFS-8 is 
0.87 and for the JFLS is 0.95.19 Test-retest reliability, assessed 
through temporal stability and the concordance correlation coef-
ficient, (CCC rho), is 0.81 for the JFLS-8 and 0.87 for the JFLS-
20.19 An effect size for the JFLS-8 of 0.41 has been reported.20 
When analyzed separately, the 3 subscales of the JFLS-20 each 
exhibited excellent psychometric properties with respect to 
modeled variance, item fit, reliability, and internal consistency 
among the 5 diagnostic groups.19 Construct and discriminant 
validity have been established through correlations with other 
measures, established between-group differences in the subscale 
and global functional limitation scores,19 and test score indepen-
dence from constructs such as depression, somatization, anxiety, 
and other clinical findings.20 The JFLS-8 and the JFLS-20 are 
also highly correlated (0.9675).19 Neither the JFLS-8 nor JFLS-20 
has been used in published HNC research. 
The TMD pain screener is a 3-item PRO with a recall period 
of the last 30 days. The first item addresses the frequency of pain 
(“no pain,” “pain comes and goes,” “pain is always present”).  A 
response of “no pain” yields a score of zero, “pain comes and 
goes” yields one point, and “pain is always presents” yields two 
points. The second item addresses pain or stiffness upon awak-
ening, and the third item is a 4-part question assessing a change 
in pain level for certain functional activities including chew-
ing, opening/moving the jaw, grinding/clenching, and kissing/
talking/yawning.  Item two and the 4 components of item three 
have dichotomous response options of “no” and “yes.”  A “no” 
is awarded zero points and a “yes” is awarded one point. Item 
scores are then summed, with a test score of zero to 7 points 
possible. A higher score indicates greater limitation. In a popula-
tion of subjects with pain-related TMD, internal consistency was 
deemed excellent (Cronbach’s α= 0.87), and temporal stability 
of individual items (κ) ranged from 0.52 to 0.78, indicating fair 
to excellent agreement. The summary test score exhibited an 
intraclass correlation coefficient of 0.83. The tool was found to 
exhibit sensitivity of 99% and a specificity of 97%. The positive 
likelihood ratio ranged from 19.2 to 44.6, varying according to 
the comparison control group, whereas the negative likelihood 
ratio was 0.01 throughout. Both positive and negative likelihood 
ratio findings exceeded the accepted benchmarks of 10 or more 
and 0.1 or less for the positive and negative likelihood ratios, 
respectively. The TMD Pain Screener has not been used in HNC 
research.21
Table 2. Outcome Measures Sorted by Task Force Rating
Rating Measure
3 Graded Chronic Pain Severity (GCPS)
3 Jaw Functional Limitation Scale (8-item version) 
3 Jaw Functional Limitation Scale (20-item version)
3 TMD Pain Screener 
2A Late Effects Normal Tissue Task Force/Subjective, Objective, Management, Analytic (LENT/SOMA)
2A European Organization of Research Treatment for Cancer Quality of Life Questionnaire-Head & Neck 35 (EORTC QLQ-HN35)
2A Liverpool Oral Rehabilitation Questionnaire
2A University of California San Francisco Oral Cancer Pain Questionnaire
2A University of Washington QOL (UW-QOL)
2A Gothenburg Trismus Questionnaire (GTQ) 
2B Manchester Orofacial Pain Disability Scale (MOPDS)
2B Subjective Oral Health Status Indicators (SOHSI)
2B TMJ Scale
2B TMD questionnaire (LDF-TMDQ, 13 items), Jaw Function Scale
2B 10-item TMJ pain questionnaire
2B Mandibular Function Impairment Questionnaire (MFIQ)
2B Modified Symptom Severity Index (Mod-SSI)
2B Tampa Scale for Kinesophobia 
2B TMD Self-efficacy Scale
2B TMD Checklist
1 Conti Anamnestic Questionnaire
1 TMD Disability Index
1 TMJ Score Questionnaire
1 Oral Impacts on Daily Performances Inventory
Abbreviations: TMD, temporomandiublar dysfunction; TMJ temporomandibular 
joint; LDF-TMDQ, Limitations of Daily Function in Temporomandibular Dysfunction 
Questionnaire
Table 3. Clinical Utility for Recommended Outcome Measures
Measure Equipment Needed Cost Ease of Use Scoring Normative Data
JFLS-8/ JFLS-20 Outcome measure, pen Free Easy Easy Not available
TMD Pain Screener Outcome measure, pen Free Easy Easy Not available
Graded Chronic Pain Scale Outcome measure, pen Free Easy Moderate Not available
Abbreviations: JFLS, Jaw Functional Limitation Scale; TMD, temporomandibular dysfunction
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Table 4. Psychometric Properties for Recommended Outcome Measures
Outcome Measure Psychometric Properties
Graded Chronic Pain Severity 
(GCPS)
Internal consistency (Cronbach’s alpha):
Characteristic Pain Intensity Measure α = 0.84 
Interference Measure α = 0.95 
Temporal stability: 
Characteristic Pain Intensity CCC = 0.91
Interference Measure CCC = 0.89
Convergent and discriminant validity of characteristic pain intensity was supported by a substantial association with 
MPI pain severity (CCC = 0.65) and smaller associations with measures of constructs other than pain (eg, depression 
[CES-D], somatic symptoms). Such validity was supported for interference by substantial associations with the MPI 
interference (CCC = 0.52) and dysfunctional measures (CCC = 0.51), and by smaller associations with measures of other 
constructs (eg, the SF-12, CES-D).23
Sensitivity to change not tested.
TMD Pain Screener Internal reliability α= 0.87
Temporal stability of the individual items (κ) ranged from 0.52 to 0.78, indicating fair to excellent agreement.22
Summary score ICC= 0.83
Validity for TMJ-related pain:
Sensitivity= 99%
Specificity= 97%
Researchers deemed the content validity to be excellent.
Sensitivity to change not tested.
Jaw Functional Limitation Scale 
(JFLS versions 8 and 20)
Construct validity was established via low correlations with depression, anxiety, somatization, pain interference, pain-
free opening, and palpation sensitivity, and via moderate correlations with pain and jaw symptoms.20
Internal consistency (Cronbach’s alpha):
JFLS-8 -  α = 0.87
JFLS-20 -  α  = 0.95
Temporal stability19: 
JFLS-8 CCC= 0.81
JFLS-20 CCC= 0.87 
Sensitivity to change not tested.
Abbreviations: CCC, concordance correlation coefficient; MPI, Multidimensional Pain Inventory; CES-D, Center for Epidemiological Studies-Depression Scale; SF-12, 
Short Form-12, TMD, temporomandibular dysfunction; TMJ, temporomandibular joint
The GCPS (version 2.0) is an 8-item PRO. In general, symp-
tom recall is for the last 30 days; however, one item has a 24-hour 
recall and another item has a 6-month recall period. Six of the 
items are scored on an 11-point Likert scale, with a response 
of zero indicating no interference or pain and a response of 10 
indicating “pain as bad as could be” or “unable to carry on any 
activities.” Item one requires the patient to report the number of 
days the patient experienced facial pain in the past 6 months, and 
item 5 requires the patient to report the number of days facial pain 
limited performance of usual activities in the past 30 days. Scores 
are calculated for 3 subscales: the characteristic pain intensity 
score, which ranges from 0–100, is calculated as the mean 
intensity ratings for reported current, worst, and average pain; 
the disability score, which ranges from 0–100, is calculated as 
the mean rating for difficulty performing daily, social, and work 
activities; and the disability points score, which ranges from 0–3, 
is derived from a combination of ranked categories of number 
of disability days and disability score. Subscale scores for pain 
intensity and disability are combined to calculate a chronic pain 
grade that enables classification of chronic pain patients into 5 
hierarchical categories: grades 0 (no pain) to IV (high disability-
severely limiting).22
The GCPS is a reliable and valid instrument that assesses 
the constructs of pain intensity and pain-related disability. The 
measure’s psychometric properties were studied in a population 
of patients with back pain, headache, and TMJ disorders. The 
internal consistency was measured with Cronbach’s α = 0.84 
for the pain intensity subscale and Cronbach’s α = 0.95 for the 
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pain-related disability subscale. The temporal stability (2–7 days) 
was high for pain intensity (CCC = 0.91), pain-related disability 
(CCC = 0.89), and chronic pain grade (weighted kappa = 0.87).22 
Among patients with moderate to severe chronic musculoskeletal 
pain, the GCPS has been shown to be modestly responsive to 
changes after 12 months of treatment with an efficacious pain 
intervention, with standardized moderate effect sizes for the 
intensity and disability sub-scales of 0.41 and 0.43, respectively. 
Among participants with chronic knee or hip pain, the standard-
ized effect size for the GCPS intensity was 0.32.23 The GCPS has 
not been used in HNC research.
“Unable to Recommend at This Time” TMD Outcomes Measures
Sixteen outcome measures received a score of 2 and are not 
recommended at this time for use by physical therapists treat-
ing individuals with TMD in the setting of HNC. A score of 2 
is further categorized as 2A if the measure has been used in the 
HNC literature or 2B if there is no published evidence that the 
tool has been used in HNC-related research. Six PROs were 
designated a rating of 2A, including the EORTC QLQ H&N43,24 
University of Washington Quality of Life (UW-QOL),25,26 
Liverpool Oral Rehabilitation Questionnaire version 3 (LORQ),27 
University of California San Francisco (UCSF) Oral Cancer Pain 
Questionnaire,28 the Gothenburg Trismus Questionnaire (GTQ),29 
and the Late Effects in Normal Tissues Subjective, Objective, 
Management and Analytic Scales (LENT/SOMA).30 
Two HNC-specific QOL measures were included in the 
review, the EORTC QLQ H&N 43 and the UW-QOL. The 
EORTC QLQ H&N43 is the most recent revision of the EORTC 
QLQ-H&N 35. It currently lacks psychometric studies to support 
its use. More importantly, similar to the UW-QOL, the EORTC 
QLQ-H&N43 is a measure designed to quantify health-related 
QOL and therefore provides a test score interpreted as an overall 
QOL score for many constructs, not a score specific to TMD. As a 
result, these two HNC-specific QOL measures cannot be recom-
mended solely for quantification of TMD dysfunction.
The LORQ is a 40-item measure developed through expert 
opinion. It addresses issues related to oral function, oro-facial 
appearance, social interaction, and dentures/dental prostheses. 
While the tool is relevant to the HNC population, it lacks strong 
psychometric properties and easy accessibility to scoring and 
interpretation. In addition, over half of the questions pertain 
to oral prosthetics, therefore decreasing its utility for a large 
portion of the HNC population.27 The UCSF Oral Cancer Pain 
Questionnaire is an 8-item PRO used to quantify patients’ pain 
levels before and after surgical resection for oral cancer. Items 
one, 3, and 5 evaluate the intensity, sharpness and throbbing 
nature of pain when the patient is not engaged in oral function. 
Items 2, 4, and 6 measure the intensity, sharpness, and throbbing 
nature of pain during oral function (talking, eating, and drink-
ing).28 Although some of these items are related to TMJ func-
tion, this tool is not specific to TMD and has not been validated 
for patients with TMD. In addition, the measure is not easily 
accessible to clinicians. The GTQ is the only measure reviewed 
specifically designed to measure trismus.29 Unfortunately, the tool 
is not easily accessible and lacks supporting research. The LENT/
SOMA scale addresses radiotherapy toxicities in patients with 
HNC and is therefore not relevant for use by physical therapists.30 
Ten PROs reviewed received a 2B rating, including: Subjective 
Oral Health Status Indicators (SOHSI),31,32 10-item TMJ Pain 
Questionnaire,33 Mandibular Function Impairment Questionnaire 
(MFIQ),34 Modified Symptom Severity Index (SSI),35 TMD 
Checklist,36 TMJ Scale,19 TMD Questionnaire (LDF-TMDQ), 
which is also known as the Jaw Function Scale,37 the Manchester 
Orofacial Pain Disability Scale (MOPDS),38 Tampa Scale for 
Kinesiophobia,39 and the TMD Self-efficacy Scale.40 
Although the SOHSI, 10-item TMJ Pain Questionnaire, 
MFIQ, Modified SSI, and TMD Checklist may appropriately 
measure the construct of TMD dysfunction, the questionnaires 
and information on scoring and interpretation are not easily 
accessible by clinicians and therefore cannot be recommended. 
The TMJ Scale is, however, accessible to clinicians, but at a 
financial cost. It is also 97-items in length and therefore not 
feasible for use in a busy clinical setting.19 Our review also found 
that the LDF-TMDQ and the MOPDS have been developed in 
other countries and may lack validity in the United States. Two 
PROs, Tampa Scale for Kinesiophobia, and TMD Self-Efficacy 
Scale, may be of benefit for use in a holistic assessment of TMD, 
however, do not specifically address the construct of TMD and 
therefore cannot be recommended at this time.
“Not Recommended” TMD Outcome Measures
Four outcome measures were given the lowest score of 1 
and are not recommended secondary to limited to no available 
research supporting the psychometric properties of the tools 
across all patient populations. These outcome measures include 
the Conti Anamnestic Questionnaire,41 the Oral Impacts on Daily 
Performance,42,43 TMD Disability Index,44 and the TMJ Score 
Questionnaire.45 
DISCUSSION
The APTA’s Oncology Section Head and Neck EDGE Task 
Force recommends that physical therapists use the GCPS, JFLS-8 
or JFLS-20, and/or the TMD Pain Screener to quantify TMD in 
patients with HNC. These measures merited a score of 3, “recom-
mended,” because they demonstrate good psychometric proper-
ties, but have not been tested or utilized in HNC literature. Each 
of the recommended measures can be found in the Diagnostic 
Criteria for Temporomandibular Disorders (DC/TMD), which is 
a compilation of clinical and patient-reported measures designed 
to assess TMD in clinical and research settings.46 The DC/TMD 
has two components, Axis I and Axis II.  Axis I of the DC/TMD 
includes the TMD Pain Screener, a symptom questionnaire, demo-
graphics, and a clinical examination. Axis II includes various 
PROs addressing constructs related to QOL, anxiety, depression, 
and TMD, including the JLFS-8, JLFS-20, and GCPS.47
Rehabilitation Oncology
Vol. 33, No. 2, 2015
12
Only 6 of the 22 measures reviewed in this study have been 
used in the HNC literature, all of which were not recommended 
at this time due to concerns regarding tool accessibility, clinical 
utility, test score interpretation specifically for TMD dysfunc-
tion, and availability of psychometric data to merit their use. 
Given the lack of PROs related to TMJ dysfunction designed 
for the HNC population, physical therapists are left to use 
TMJ-related outcome measures that have been designed for other 
patient populations whose needs may be quite different than the 
particular concerns of a patient with HNC. Additional research 
is therefore required to determine the psychometric properties of 
the measures recommended by the HNC EDGE Task Force in the 
HNC population, and to further study relevant PROs that could 
not be recommended by the Task Force at this time. For example, 
the TMD Disability Index is similar in format to the Oswestry 
Disability Index and Neck Disability Index, both frequently used 
PROs in the physical therapy profession for back and neck pain, 
and has been used in physical therapy research.48-51 Despite its 
use, the TMD Disability Index received a rating of “not recom-
mended” because psychometric properties for the measure have 
not been reported. 
A systematic review of the literature to identify publications 
utilizing PROs suitable for oral and maxillofacial surgery found 
there are numerous questionnaires available, however selecting 
the most appropriate one can be difficult.52 Ojo and colleagues53 
explored HNC QOL instruments and determined that cross-
study comparisons have been hampered by the heterogeneity 
of measures used in research and the fact that reviews of HNC 
instruments have not been comprehensively studied. Given the 
volume and heterogeneity of PROs there is no gold standard 
HNC-specific TMD questionnaire.53 
Similar to the Oncology Section’s HNC EDGE Task Force’s 
reviews on neck and shoulder PROs and measurement of external 
lymphedema for HNC survivors, 54,55,58 the obvious limitation in 
this review, was that very few of the measures reviewed have 
actually been utilized to evaluate TMJ-related impairment and 
disability in the HNC patient population. Referral to physical 
therapy for HNC related-TMD is underutilized.56 In addition, 
there are a limited number of investigators with expertise in 
TMJ-related impairments and function conducting research in the 
HNC population. Prolonged survivorship due to improved medi-
cal management of HNC increases the importance of restoring 
optimal function in order to improve QOL and function.56 Given 
the rise in HPV-associated HNCs, improvements in early detec-
tion, prevention, and medical management strategies, patients 
with HNC may have unmet physical therapy needs to reduce or 
prevent TMJ disability. 
To our knowledge, this is the first attempt at providing recom-
mendations for TMD-specific PRO utilization by physical thera-
pists treating patients with HNC. Future research should consider 
the psychometric properties of PROs, including establishment of 
normative values and responsiveness to change, addressing TMD 
in the HNC population. Although great strides have been made in 
the assessment of PROs and QOL in HNC, more work is needed 
to improve the clinical utility of these measures in order to link 
research to clinical practice.9,53,57 
CONCLUSION
The HNC EDGE Task Force recommendations provide 
physical therapists with evidence-based outcomes measure 
recommendations for use with patients with HNC presenting with 
TMD. The HNC EDGE Task Force recommends 4 measures that 
are easy to use in the clinic with good psychometric properties. 
These measures fulfill Medicare functional outcome reporting 
requirements and can provide reliable and valid data from which 
to quantify patient response to physical therapy interventions.
Our review reveals a gap in psychometric research evaluat-
ing properties of available TMJ-related PROs applied in the HNC 
population. The HNC EDGE Task Force reviews include recom-
mendations for other areas that affect HNC patients that fall under 
the scope of practice for physical therapy such as neck,54 shoul-
der,55 and lymphedema.58 Further research is needed to evaluate 
psychometric properties of PROs for use in the HNC patient 
population. Studies evaluating HNC-specific PROs’ responsive-
ness to change, generation of normative values, and reliability 
and construct validity in the HNC patient population are needed. 
The HNC EDGE Task Force recommendations are a first-step to 
fill the gap in knowledge of useful, relevant, and patient friendly 
TMJ-related outcome measures for the HNC patient population.
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ABSTRACT
Background: Survivors of head and neck cancer (HNC) and 
its treatment experience high rates of lymphedema. Unlike the 
extremities, the head and neck is difficult to measure and does 
not easily lend itself to having a contralateral side for comparison. 
Being an irregularly shaped part of the body, measures of edema 
for the extremities cannot be adapted for the head and neck. The 
need exists for outcome measures to objectively quantify head 
and neck lymphedema using evidence-based practice guidelines. 
Purpose: The purpose of this study is to identify and recom-
mend external edema outcome measures for lymphedema in the 
HNC population. Methods: A systematic review of the litera-
ture on edema measures for use in the HNC patient population 
was conducted. The Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) model was used to 
guide which articles were chosen for inclusion, determination 
of eligibility, screening, and identification for the final review. 
Recommendations are based on the quality of psychometric 
properties, clinical feasibility, and previous use in HNC-related 
research. Six edema outcome measures were reviewed and none 
are recommended at this time; however, several hold great prom-
ise for future use in the clinic. Conclusions:  This systematic 
review provides an overview for physical therapists on measures 
of external edema for the HNC patient population. The edema 
measures included in this review have been tested on HNC 
patients but have not been rigorously tested due to their novelty. 
At this time, no outcome measures for objectively quantifying 
external edema for the HNC population can be recommended. 
There is need for more research on this topic prior to providing 
definitive recommendations.
Systematic Review Registration Number: PROSPERO 
CRD42013004898
Key Words: lymphedema, head and neck cancers, measurement
INTRODUCTION
Cancers of the head and neck (HNC) involve the oral cavity, 
pharynx, larynx, paranasal sinuses, nasal cavity, salivary glands, 
upper esophagus, face, associated musculature, and/or bone and 
some thyroid cancers.1 Head and neck cancer represents 3% of 
all cancer survivors in the United States and is considered an un-
derstudied tumor type.2 The 5-year relative survival rate of these 
cancers widely varies—94% (lip cancer), 74% (salivary gland), 
and 30% (hypopharynx, and “other” cancers of the oral cavity 
and pharynx)2 with approximately 291,108 people living with oral 
cavity and pharyngeal cancers in the United States in 20123– like-
ly an underestimate since laryngeal, thyroid, and upper esopha-
geal cancers are also head and neck cancers.3,4 Despite the rar-
ity of HNC, disability and other side effects are highly prevalent. 
Lymphedema is known to affect the majority of HNC survivors 
(60-80%) affecting external structures (eg, outward and obvi-
ous swelling of the neck, head, and face), internal structures (eg, 
tongue, oral cavity, pharynx, hypopharynx, larynx, trachea, and 
esophagus), or a combination of both.5,6 Head and neck cancer 
survivors usually have one or multiple treatment modalities. For 
example, tumor and lymph node resection and/or radiation, che-
motherapy, or combined chemotherapy and radiation (CCR).7,8 
These treatments can be a grueling experience with serious side 
effects (eg, mucositis, cachexia, fatigue, oral and non-oral pain) 
that may require feeding tube placement.9 
Location of the tumor, tumor and lymph node resection, ra-
diation, and multiple modality treatment are all associated with 
lymphedema of the head and neck.5 Other posttreatment factors 
such as muscle guarding, abnormal posture, and reduced move-
ment in the affected areas may also contribute to lymphedema 
among HNC survivors.10 Lymphedema, left untreated, can have 
serious consequences resulting in risk for recurrent infection such 
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as cellulitis, and interference with the ability to breathe, swallow, 
and/or speak—key functions of life.6
The 5-year relative survival rate from HNC, particularly for 
those with human papillomavirus (HPV) positive tumors, is im-
proving. Survival rates (relative and absolute) are high. For ex-
ample, survival rates for oral cavity and pharyngeal tumors are 
62.7% and for laryngeal cancers, 60%. With increased survival, 
it stands to reason that more HNC survivors will be living with 
long-term cancer-related lymphedema.6,12 Head and neck cancer 
survivors diagnosed with lymphedema are commonly referred to 
physical therapy for lymphedema management.13,14 Complete as-
sessment of lymphedema involves patient subjective complaints, 
physical examination (ie, pitting, tissue texture), and objective 
tests and measures.15-17 Reliable and valid measures are necessary 
for clinicians to accurately assess and document patient progress 
and guide clinical decision-making.
This systematic review is part of the Evaluation Database to 
Guide Effectiveness (EDGE) activities of the American Physical 
Therapy Association Oncology Section’s Head and Neck Cancer 
Task Force. The purpose of this systematic review is to identify 
and provide recommendations of clinically feasible and relevant 
objective tests and measures of edema for HNC survivors with 
cancer-related lymphedema.
DATA & METHODS
The authors registered this systematic review on PROSPERO 
(CRD42013004898). The search was limited only to studies that 
report on measurement of edema due to cancer treatment-related 
lymphedema of the head and neck. Because little research exists 
on concerns of HNC survivors that falls within the scope of 
physical therapy practice, we placed no limits on publication 
dates or level of evidence. We conducted a search of literature 
databases (PubMed, PEDro, EBSCO Host, Medline, PsycInfo, 
and Cochrane Database) using the following key words in all 
combinations: edema, human, lymphedema, cancer, head, neck, 
radiation, radiotherapy, surgery, neck dissection, face, measure-
ment, outcome, outcome measure, radiation fibrosis, lymphosta-
sis, inflammation, reliability, and validity. Articles were limited 
to studies on humans and published in English. Duplicates were 
removed and abstracts for all citations were screened to determine 
if they were to be included in the final review. Figure 1 illustrates 
the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) process used for the literature search.
Two investigators (AMF and BAS) independently completed 
a search of the literature using the databases and personal files 
of published articles not included in the literature databases as 
mentioned earlier in June 2014. This provided verification of the 
search results. The investigators then independently reviewed 
the abstracts of the search results and eliminated non-relevant 
articles based on the predetermined inclusion criteria (English 
language, any date of publication, any level of evidence) and 
exclusion criteria (no requirement of a physician prescription or 
performance of a medical procedure for measuring edema, non-
human sample, quality of life study). The measures of edema 
identified by the authors were divided between reviewers, who 
independently retrieved relevant studies and full-text articles for 
each measure to assess clinical feasibility, psychometric proper-
ties, and relevance to the HNC patient population. The primary 
reviewer completed the HNC Task Force Outcome Measure 
Rating Scale Form (Table 1) for each assigned measure. The 
risk of bias of measure assessment was addressed by ensuring a 
secondary review for all measures. In the case of a discrepancy 
in rating between reviewers, two other investigators were avail-
able to evaluate the reviews and determine the decision outcome, 
along with the other two investigators, until total agreement was 
reached. Outcome measure recommendations were agreed upon 
using the EDGE criteria resulting in an ordinal score with anchors 
at 1 (measure is not recommended) and 4 (measure is highly 
recommended) (see Table 1).18 
RESULTS
Using our keywords, we identified 25,007 records. All 
duplicates were removed which resulted in 11,337 articles. 
Eighty-six outcome measures of lymphedema were identified; 
40 were patient reported outcomes (PRO) (represented in 141 
articles) and the remainder were clinical measures (represented 
in 254 articles). We excluded 46 measures which had only one 
article addressing the measure. Using the remaining articles, the 
investigators generated a list of 12 measures of edema for HNC 
treatment-related lymphedema. Of these clinical measures, only 7 
represented measurements of external edema for lymphedema of 
the head and neck that can be performed by physical therapists: 
real-time ultrasound, 3-dimensional (3D) laser scanning, tissue 
dielectric constant (TDC) method, M.D. Anderson Cancer Center 
– head and neck lymphedema rating scale (MDACC-HNLRS), 
and the ALOHA method (circumferential volume revised for 
head and neck), frustum volume estimation, and disk model 
method. One hundred thirty-nine references were included in the 
review (see Figure 1 and Table 1). 
Figure 1. PRISMA model.
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“Highly Recommended” and  
“Recommended” Edema Outcome Measures
In order to reach this level of recommendation, the measure 
must have evidence supporting excellent psychometric properties 
and clinical utility. The measure should also have been tested in 
the HNC population. Of the 6 measures, none reached the level of 
“highly recommended” or “recommended,” per the requirements 
outlined in Figure 2. 
“Unable to recommend at this time”  
Edema Outcome Measures
This recommendation has two levels depending on whether 
the measure has been used in the HNC patient population (2A) 
or not (2B). Four types of measures reached this level of recom-
mendation. Three of these use technological devices to measure 
external edema—ultrasound, 3D scanning, and TDC. The final 
type is standardized tape measurement of the head, neck, and 
face. Included in this final type are two different approaches—the 
MDACC-HNLRS and the ALOHA tape measurement system. All 
have been used in the HNC population.
Real-time ultrasound measures skin-to-bone distance, skin 
thickness, subcutaneous thickness, and/or resistance to compres-
sion. Measurement of skin to bone distance at the mandibular 
ramus, angle and hyoid using a 7.5 MHz linear transducer was 
found to be reliable in healthy individuals (intraclass correla-
tion coefficients ICC, ranged from 0.88 to 0.97).14 Skin thick-
ness (r = 0.95) and subcutaneous thickness (r = 0.84) have been 
shown to be strongly correlated with duration of lymphedema in 
women with breast cancer-related lymphedema.19 At the time of 
this writing and to the best of our knowledge, no studies have 
formally investigated the responsiveness of ultrasound as a 
measure of edema among those with HNC-related lymphedema. 
However, one study showed a significant reduction in skin-
to-bone distance after patients with HNC-related lymphedema 
received a course of manual lymphatic drainage and compression 
therapy.14 Significant differences in skin thickness were found in 
patients who received systemic enzyme therapy after undergoing 
bimaxillary orthognathic surgery compared to those who did not 
receive systemic enzyme therapy.20 
Three-dimensional scanning is a more recent application 
in its use for edema measurement. It has been used in a vari-
ety of industries—engineering where it is used for design and 
building projects;21,22 forensics where it is used to estimate size, 
volume, and topography of missing body parts;23,24 manufactur-
ing where it is used for machining;25,26 and dentistry where it is 
used in the creation of dental implants and dentures.27,28 Three-
dimensional scanning uses laser technology to scan the body part 
to be measured. It is a noninvasive approach with no radiation 
exposure and excellent reproducibility, with an error of less than 
one tenth of a millimeter.29-31 However, Harrison et al reported a 
measurement error range between 0.3-4.0 cm3 largely attributed 
to changes in positioning.32 The sensitivity33 and reliability29-40 
of this method of edema measurement are high. Ramos and 
colleagues33 report that 3D imaging is sensitive, reproducible, and 
significant in detecting change in those with breast cancer-related 
lymphedema with initial volumes of 500 mL or less. The mean 
error of measurement for volume measured using 3D imaging 
has been found to be within 3.5%.39 Kau et al40 measured facial 
morphology in 473 male and female subjects using this technol-
ogy. The average linear distance among male subjects ranged 
from –6.30 to 4.44 mm, with similar measurements among 
females ranging from –6.32 to 4.25 mm.40 Together, these stud-
ies provide reference values for comparison for future studies. 
Limited research33,39,40 using this method in the HNC survivor 
population exists at this time. However, this method allows one 
to measure any linear distance from any point to another in the 
affected and unaffected areas.
Like the 3D scanning technique, the TDC has also been used 
in health research and other industries. The Moisture Meter D 
(Delfin Technologies, Kuopio, Finland), is the only TDC device 
that has been tested with HNC survivors to measure cancer-
related lymphedema. Inter-observer reliability, measured by the 
ICC has been found to be 0.973 in previous research.41-43 Internal 
consistency has not been reported nor has the measurement error 
for the head and neck. The TDC device measures physiologic 
properties of biological fluid to a depth of between 0.5 mm – 5 
mm for the ventral forearm and 2.5 mm on the lateral thorax. 
These depths not only vary by body location but also depend on 
Table 1. EDGE Head and Neck Cancer Task Force Outcome Measure Rating Form
EDGE Head and Neck Cancer Task Force Outcome Measure Rating Form
4 Highly Recommend The outcome has excellent psychometric properties and clinical utility; the measure has been used in research on individu-als with or post head and neck cancer.
3 Recommend The outcome measure has good psychometric properties and good clinical utility; no published evidence that the measure has been applied to research on individuals with or post head and neck cancer.
2A Unable to Recommend at this time
There is insufficient information to support a recommendation of this outcome measure; the measure has been used in 
research in individuals with or post head and neck cancer.
2B Unable to Recommend at this time
There is sufficient information to support the recommendation of this outcome measure; no published evidence that the 
measure has been applied to research on individuals with or post head and neck cancer.
1 Do Not Recommend Poor psychometrics &/or poor clinical utility (time, equipment, cost, etc).
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the diameter of the probe used for TDC.41 Recently, the TDC has 
been tested on the forehead and just below the maxilla (cheek) 
to measure the TDC up to a depth of 0.5 – 2.5 mm, but the 
thickness of the skin was a mediator in the measurement. This 
means that as tissue thickness increases in the forehead, the TDC 
value is reduced, but the opposite is true for the maxillary TDC 
measurement. However, in general, as tissue thickness increases, 
so does the TDC value indicating increased water content.44 Only 
a few studies have used this method with HNC survivors, but it 
has not yet been tested for safety, efficacy, diagnostic reliability, 
and validity with large samples. Nixon et al45 report interrater 
reliability as 0.97. They also report that the TDC, as measured 
by the Moisture Meter D, was able to discriminate between HNC 
survivors and healthy controls (t = 8.97, p < 0.001). The TDC 
was also correlated with linear tape measurements of the head 
and neck area (rho = 0.37-0.38), but not with the rating scale used 
by the MDACC-HNLRS. This study used a small sample size of 
40—20 HNC survivors and 20 healthy controls.43 At the time of 
the writing of this paper, this device is experimental in the United 
States in terms of its application in assessing edema of the head 
and neck. Unfortunately, none of the studies examined for this 
review considered obesity or tissue fibrosis as possibly leading to 
inaccurate estimates of fluid in the head and neck. 
The tape measurements are based on dental and maxillofa-
cial surgery measurement standards first described by Gabka et 
al46 and later modified by Schultze-Mosgau et al.47,48 Both were 
further adapted by Smith and Lewin to include neck measure-
ments used in the MDACC-HNLRS.17 The facial measures rely 
on the use of bony landmarks of the face and head.17,43,44 Both 
MDACC-HNLRS and the ALOHA approach use linear distance 
measures. The MDACC-HNLRS uses 12 measures adapted from 
Gabka et al.46  Two are point-to-point measures (mandibular angle 
to angle and tragus to tragus), 7 are facial measures (tragus to 
mental protuberance; tragus to mouth angle; mandibular angle 
to nasal wing; mandibular angle to medial canthus; mandibular 
angle to lateral canthus; mental protuberance to medial canthus; 
mandibular angle to mental protuberance), and 3 are circumfer-
ential neck measures (superior neck immediately beneath the 
mandible; medial neck midway between the superior and inferior 
neck; inferior neck at the base of the neck).17,46  The ALOHA 
tape measurements utilize one point-to-point measure (ear to ear 
beginning at the inferior ear lobe/face junction of the left and 
right meeting at a point 8 cm inferior to the lower lip); 3 circum-
ferential measures (lower neck circumference at the base of the 
neck; upper neck circumference inferior to the mandible; length 
from lip to lower neck circumference along the midline inferior 
lower lip to lower neck circumference). Purcell et al43 compared 
3 measurement methods—MDACC-HNLRS, ALOHA, and TDC 
alone. The ALOHA trial showed high interrater reliability for 3 
tape measures with ICCs ranging from 0.948 (ear to ear length), 
0.969 (upper neck circumference) and 0.979 (lower neck circum-
ference).43 The only tape measurement found not to have high 
interrater reliability was the lip to lower neck circumference 
length (ICC = 0.420).43 Unlike the TDC, tape measures did not 
significantly discriminate between HNC survivors with lymph-
edema and healthy controls.43 However, the authors recommend 
the tape measures as sensitive enough to measure within-person 
change over time, but did not provide evidence to support this 
claim.43 Moreover, from a practical perspective, tape measure-
ment takes a great deal of time to perform, making it difficult 
to measure irregularly shaped parts of the face and head such as 
the edema in the mandibular, auricular, nasal, orbital and sub-
mandibular areas. Table 2 provides a summary of the psychomet-
ric properties of these measures. 
“Not Recommended” Edema Outcomes Measures
The remaining two measurements—frustum and disk model 
methods—merited a score of “not recommended.” This means 
that poor psychometrics and lack of clinical utility exists for the 
frustum and disk model methods. Both of these edema measures 
were tested together in the studies we examined; however, it is 
important to note that each is a distinct method. The frustum 
method is an ancient method used to estimate the volume of 
multi-sided pyramidal shapes. A frustum is a geometric solid 
volume measurement of a cone or pyramidal structure and is 
created by at least two planes that bisect one another to form a 
side of a cone. In contrast, the disk method relies on the sum of 
multiple circumferential measures of a cone. Both methods are 
ideal for conical measures, and therefore, have been limited to 
use in the extremities.48,49 An exception to this is one study that 
used a sample of 4 patients with head and neck lymphedema, in 
which the frustum method was calculated based on circumferen-
tial tape measurements of the head.50 The frustum and disk model 
methods have also been used to measure volume of the prostate—
another irregularly shaped body part. The frustum method was 
found to underestimate prostate volume by 50% when compared 
to planimetry and overestimated volume compared to ultrasound 
guided MRI.45 While these methods are useful for the extremi-
ties, only the frustum method has been used on a small sample 
of HNC survivors50 at the time of this writing. Unfortunately, no 
psychometric data are reported for the HNC patient population 
using these measures (see Table 2).
DISCUSSION
While smoking and/or alcohol abuse are common causes of 
HNC,1 specific types of HPV cause nearly 32% of all HNC cases 
and this incidence is expected to rise.12 With this growth, we ex-
pect that physical therapists will experience increased referrals for 
patients with HNC. In addition to lymphedema, HNC survivors 
undergoing treatment will have reduced dietary intake, with 37% 
to 68% experiencing moderate to severe pain, impaired swallow-
ing, xerostomia, taste, and hoarseness.52 Conical measures using 
circumferential measures or formulae dependent on circumferen-
tial measures (eg, frustum, disk model methods) are easy to use 
to measure edema of the extremities, but they do not adequately 
measure edema in the head and neck. These methods may un-
derestimate volume of the head and neck.51 Aside from surgical 
anatomy changes and associated side effects, the addition of side 
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effects associated with chemotherapy, radiation, or CCR increases 
the risk of lymphedema of any of the structures targeted by cancer 
treatment. For example, radiation-induced tissue fibrosis will in-
clude damage to the remaining lymphatic structures in the treated 
area.54
Subjective information through self-reports such as heavi-
ness, tightness, and firmness5,6 along with objective information 
provided by clinical measurement of lymphedema can provide 
information to determine successful outcomes when treating 
HNC survivors. Lymphedema is a multi-faceted diagnosis based 
on the presence or absence of skin integrity, color, edema, pit-
ting, positive Stemmer’s sign, and malformations associated with 
lymphostasis and infection.15 Therefore, using edema measure-
ment as a singular indicator of lymphedema can be misleading 
in determining the severity of the lymphedema.16,55 However, in 
the head, face, and neck, edema drastically changes one’s appear-
ance and may impair the ability to breathe, swallow, and vocalize, 
making external measures of edema a crucial part of any physi-
cal therapy examination, evaluation, and assessment of the HNC 
survivor. It is important that physical therapists treating the HNC 
survivor with lymphedema have reliable and valid measures of 
edema that are clinically feasible and have realistic and reason-
able associated costs. While there are also internal measures of 
lymphedema, these are invasive and require technical procedures 
that fall outside of the scope of physical therapist practice. For ex-
ample, a bronchoscopy is performed by an otolaryngologist to as-
sess internal swelling as well as check for cancer recurrence in the 
oropharyngeal cavity, as Deng and colleagues have done. Bron-
choscopy is not risk-free. These risks include aspiration, vocal 
Table 2. Psychometric Properties and Clinical Utility of External Edema Measures
Measure Rating Relevant Psychometric Properties Clinical Utility
Ultrasound 2A
Test-retest reliability14
ICC = 0.88-0.97
SEM: 0.50-0.64 mm
MDC95%: 1.37 – 1.78 mm
MCID, reference values: NA
Intensive training is required. Equipment (ultrasound unit) is 
costly, but is becoming more readily available in physical therapy 
clinics due to usage with musculoskeletal conditions. However, a 
higher frequency probe is typically used to measure skin thickness. 
Three-dimensional 
Scanning 2A
Mean coefficient of variation for volume29
2.02 – 5.09%
Mean error29,30,34
0.31 – 0.86 mm 
0.01 – 0.23 cm3 
SEM, MDC, MCID: NA
Reference values40
·	 Males: –6.30 to 4.44 mm
·	 Females: –6.32 to 4.25 mm
Intensive training is required. Equipment (3-dimensional imaging 
system) and computer software is costly and not readily available 
in clinic. Requires standardized patient positioning.
Tape Measurement 2A
Interrater reliability43
ICC: 0.42 – 0.95
Concurrent validity with Moisture Meter43
r = 0.17 –0.38, p > 0.05 for all measurements 
except lip to lower neck circumference
SEM, MDC, MCID, reference values: NA
Easy to use. Minimal training required. Equipment (tape measure) 
is inexpensive and readily available. Requires standardized patient 
positioning. 
Tissue Dielectric 
Constant 2A
Intrarater reliability43
ICC: 0.97
Interrater reliability43
ICC: 0.97
Concurrent validity with MDACC level 43
r = 0.58
SEM, MDC, MCID, reference values: NA
Easy to use. Minimal training required. Equipment (Moisture 
Meter™) is costly and not readily available in clinic. 
Abbreviations: ICC: intraclass correlation coefficient; SEM: standard error of measure; MDC: minimal detectable change; MCID: minimal clinical important difference; 
NA: not available; MDACC: MD Anderson Cancer Center Head and Neck Lymphedema Rating Scale
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cord damage, bleeding, oxygen desaturation, bronchospasm, fe-
ver, pneumonia, pneumothorax, and death.56,57 Physical therapists 
specializing in HNC would benefit from having well-formed re-
lationships with physician or speech therapy practitioners to take 
advantage of information resulting from imaging procedures out-
side the PT scope of practice. Additional measurements could be 
taken and internal and external volume could then, hypothetically, 
be calculated. Three-dimensional scanning, ultrasound, and TDC 
can be performed by physical therapists; however, each require 
additional training on the use and application of these methods. 
Three-dimensional scanning has a steep learning curve because it 
requires that the user know how to use the scanner and requires 
multiple images to render a 3D image. The software to create 
these images is complex and difficult to learn. Further, the cost of 
a 3D scanner, software and software training is cost-prohibitive 
for the average clinical setting. Real-time ultrasound, on the other 
hand, is increasingly utilized in physical therapy clinics and those 
who already use it for evaluation of treatment of patients (such as 
urinary incontinence or adhesive capsulitis) may find it easy to 
use in the HNC patient population. Finally, TDC appears to be the 
easiest to use, set-up, and interpret.
Quantifying edema reduction is crucial to gauge the effect 
of treatment for lymphedema in the head and neck. It presents a 
unique measurement challenge in effectively treating HNC sur-
vivors. Edema measurement will fulfill new Medicare outcomes 
documentation requirements to demonstrate reduction in volume 
due to external lymphedema. At this point, there is no gold stan-
dard to measure edema in the head and neck. Common practice 
involves linear distances of the face and circumferential mea-
sures of the neck—such as those used in the MDACC-HNLRS 
and ALOHA methods. However, neither of these methods actu-
ally measure volume but provide a way to document reduction in 
linear distance that is reasonably expected to reflect a reduction 
in volume in response to treatment. The advantage of the linear 
distances used in these measures is that clinically speaking the 
baseline of these measures could be measured using diagnostic 
MRI or CT scan. However, this approach involves the coopera-
tion of physicians—particularly radiologists—and is not typically 
measured as part of clinical standards of care. Another advantage 
of the MDACC-HNLRS and ALOHA methods is that both pro-
vide a systematic way to measure edema. The ALOHA method 
also incorporates measurement of the TDC and, similar to the 
MDACC-HNLRS, also uses tape measurements and classification 
of HNC lymphedema characteristics. These approaches are clini-
cally feasible, cost-effective, and not time-intensive. The linear 
measurements are estimated by the authors to take approximately 
5 minutes to measure by clinicians experienced with HNC sur-
vivors, making them not time intensive. However, the inclusion 
of the TDC increases the time to complete the measurement and, 
in total (linear and TDC measurement), we estimate these could 
take up to 10 minutes. Ten minutes could take up one third of the 
time to evaluate or treat a non-complex patient, even more time 
may be required if the physical therapist needs to re-measure. At 
this point though, TDC is not commonly used clinically and is not 
likely to be found in the average clinic.
The techniques of ultrasound, 3D scanning, and TDC meth-
ods hold great promise for clinical translation but all need more 
research investigating their psychometric properties of reliability 
and validity, sensitivity to change, and references for comparison. 
All 3 are used to measure external edema and, while none ad-
dresses the measurement of internal edema, they are noninvasive 
and not dependent on a skill set possessed only by physicians. 
Like MRI and CT-scanning methods, 3D laser scanning can pre-
cisely measure external lymphedema and does not require a medi-
cal referral. The disadvantage is that the entire volume of the head 
and neck region is assumed to be included in the overall volume 
measure. To illustrate, it assumes that the scanned area is a solid 
with no “empty” spaces such as the oral cavity, sinuses, pharynx, 
larynx, and upper esophagus. Of these 3 methods dependent on 
the use of technology, 3D scanning is prohibitively expensive and 
presents a steep learning curve for the physical therapist. In ad-
dition to the 3D laser scanner (of which there are several types to 
choose), the clinic will also need to purchase 3D computer soft-
ware to measure volume. The computer programs are complicated 
and require intensive training. Other costs associated with the use 
of the 3D scanner include software training, service agreements, 
software updates, repair costs, and costs for personnel to take the 
images and render them usable in 3D software.  
In contrast, the TDC is a small hand-held device that provides 
fast and readily available measurements. The TDC measures the 
electrical properties of lymphatic fluid—not necessarily edema 
like 3D scanning—but it is comparable to the MDACC-HNLRS 
and ALOHA systems. Likewise, ultrasound holds promise and 
further research is warranted. We caution that the 3D scanners, 
real-time ultrasound, and TDC devices may be cost-prohibitive 
for a clinic to purchase.
Measurement of head and neck lymphedema poses many 
challenges to physical therapists. Methods that are clinically re-
alistic are limited and few have had in-depth testing with patients 
with HNC. Head and neck cancer is a rare tumor type and patients 
tend to be very sick during active treatment, making it difficult 
to recruit and retain large samples for research. The MDACC-
HNLRS and the ALOHA measurement systems are the best avail-
able and feasible measures for use in the physical therapy clinic. 
Collected prospectively and across clinics, these measurement 
systems may provide important data for future research and com-
parability across clinics.
While we focused on measurement of external edema for the 
HNC survivor with cancer-related lymphedema, it is clear that 
much more research needs to be conducted to address the com-
plex cluster of issues typical of lymphedema.  Future research 
will address this through the review of PROs related to QOL and 
lymphedema.
CONCLUSIONS
Measurement of lymphedema of the head and neck is in its 
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infancy. Few methods exist to calculate volume and/or physiologi-
cal properties that characterize lymphedema of the head and neck. 
Volume assessment using tape measures and specific landmarks 
are the most commonly used method currently, but other methods 
such as 3D scanning, ultrasound, and TDC hold great promise. 
However, because of the lack of good psychometric properties 
or clinical utility, no outcome measures for objectively quantify-
ing external edema for the HNC population can be recommended 
at this time. The future development and application of these 
devices to measure edema in HNC survivors with lymphedema 
merits systematic and comparative research to evaluate measure-
ment properties such as reliability, validity, sensitivity to change, 
and normative values. Much research needs to be conducted to 
develop and compare a variety of methods for edema of the head 
and neck. We recommend that physical therapists fully weigh the 
advantages and disadvantages of any measure of edema while 
treating HNC survivors. 
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Data collection process 
10
Describe method of data extraction from reports (eg, piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators. 16
Data items 
11
List and define all variables for which data were sought (eg, PICOS, funding sources) and any 
assumptions and simplifications made. 16
Risk of bias in individual 
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data synthesis. 
16
Summary measures 13 State the principal summary measures (eg, risk ratio, difference in means). NA
Synthesis of results 
14
Describe the methods of handling data and combining results of studies, if done, including measures 
of consistency (eg, I2) for each meta-analysis. NA
Rehabilitation Oncology
Vol. 33, No. 2, 2015
22
REFERENCES
1.     National Cancer Institute. Head and neck cancers. National 
Cancer Institute at the National Institute of Health Web 
site. http://www.cancer.gov/cancertopics/factsheet/Sites-
Types/head-and-neck. Updated February 1, 2013. Accessed 
November 11, 2013.
2.     Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner 
MJ, eds. SEER survival monograph: Cancer survival among 
adults: U.S. SEER program, 1988-2001, patient and tumor 
characteristics. Bethesda, MD: National Cancer Institute, 
SEER Program; 2007. 
3.     Howlader N, Noone AM, Krapcho M, et al. SEER Cancer 
Statistics Review, 1975-2012, National Cancer Institute. 
Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based 
on November 2014 SEER data submission, posted to the 
SEER web site, April 2015. 
4.     De Moor JS, Mariotto AB, Parry C, et al. Cancer survivors 
in the United States: Prevalence across the survivorship 
trajectory and implications for care. Cancer Epidemiol 
Biomarkers Prev. 2013;22(4):561-700.
5.     Deng J, Ridner SH, Dietrich MS. Factors associated with 
external and internal lymphedema in patients with head-and-
neck cancer. Int J Radiat Oncol Biol Phys. 2012;84(3):e319-
328.
6.     Deng J, Ridner SH, Dietrich MS, Wells N, Murphy BA. 
Assessment of external lymphedema in patients with head 
and neck cancer: A comparison of four scales. Oncol Nurs 
Forum. 2013;40(5):501-506.
7.     Liu M, Shi X, Guo X, et al. Long-term outcome of irradia-
tion with or without chemotherapy for esophageal squamous 
cell carcinoma: A final report on a prospective trial. Radiat 
Oncol. 2012;7:142. 
8.     Thariat J, Hamoir M, Garrel R, et al. Management of the neck 
in the setting of definitive chemoradiation: Is there a consen-
sus?  A GETTEC study. Ann Surg Oncol. 2012;19(7):2311-
2319.
9.     Romesser PB, Romanyshyn JC, Schupak KD, et al. 
Percutaneous endoscopic gastrostomy in oropharyngeal 
cancer patients treated with intensity-modulated radiotherapy 
with concurrent chemotherapy. Cancer. 2012;118(24):6072-
6078.
10.   Fialka-Moser V, Crevenna R, Korpan M, Quittan M. Cancer 
rehabilitation: Particularly with aspects on physical impair-
ments. J Rehabil Med. 2003;35(4):153-162.
11.   Howlader N, Noone AM, Krapcho M, et al. SEER cancer 
statistics review, 1975-2008. National Cancer Institute Web 
site. http://seer.cancer.gov/csr/1975_2008. Updated 2014. 
12.   Näsman A, Nordfors C, Holzhauser S, et al. Incidence of 
human papillomavirus positive tonsillar and base of tongue 
carcinoma: A stabilisation of an epidemic of viral induced 
carcinoma? Eur J Cancer. 2015;51(1):55-61.
13.   Tacani PM, Franceschini JP, Tacani RE, et al. Retrospective 
study of the physical therapy modalities applied in head and 
neck lymphedema treatment. Head Neck. 2014 Oct 21. Epub 
ahead of print.
14.   Piso DU, Eckardt A, Liebermann A, Gehrke A. Reproducibility 
of sonographic soft-tissue measurement of the  head and 
neck. Am J Phys Med Rehabil. 2002;81(1):8-12.
15.   Foldi M, Foldi E, Kublik S. Textbook of Lymphology. 6th ed. 
Munich, Germany: Elsevier; 2005.
16.   Zuther JE, Norton S. Lymphedema Management: The 
Comprehensive Guide for Practitioners. 3rd ed. New York, 
NY: Thieme; 2013. 
17.   Smith BG, Lewin JS. Lymphedema management in head 
and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 
2010;18(3):153-158. 
18.   Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA state-
ment for reporting systematic reviews and meta-analyses of 
studies that evaluate health care interventions: Explanation 
and elaboration. J Clin Epidemiol. 2009;62(10):e1-34. 
19.   Mellor RH, Bush NL, Stanton AW, Bamber JC, Levick JR, 
Mortimer PS. Dual-frequency ultrasound examination of 
skin and subcutis thickness in breast cancer-related lymph-
edema. Breast J. 2004;10:496-503.
20.   Shetty V, Mohan A. A prospective, randomized, double-blind, 
placebo-controlled clinical trial comparing the efficacy of 
systemic enzyme therapy for edema control in orthognathic 
surgery using ultrasound scan to measure facial swelling. J 
Oral Maxillofac Surg. 2013;71(7):1261-1267.
21.   Baaklini G. Optical instrumentation and nondestructive 
evaluation branch research and technology advances at 
NASA Glenn Research Center since 1941. J Aerosp Eng. 
2013;26:395-408.
22.   Huang Y, Leu MC, Mazumder J, Donmex A. Additive manu-
facturing: Current state, future potential, gaps and needs, 
and recommendations. Manuf Sci Eng. 2015(Online 2014 
Nov);137(1):014001.
23.   Buck U, Naether S, Räss B, Jackowski C, Thali MJ. Accident 
or homicide--virtual crime scene reconstruction using 3D 
methods. Forensic Sci Int. 2013;225(1-3):75-84.
24.   Davy-Jow SL, Lees DM, Russell S. Virtual forensic anthro-
pology: Novel applications of anthropometry and technology 
in a child death case. Forensic Sci Int. 2013;224(1-3):e7-10.
25.   Son H, Kim C, Kim C. Automatic 3D reconstruction of 
as-built pipeline based on curvature computations from laser-
scanned data. Construction Research Congress. 2014:925-
934.
26.   Song I, Yang J, Shimada K. Development of sketch-based 
3D modeling system for rapid generation and evaluation of 
automotive seat shape using reference models. J Mech Des. 
2014;136(5):051001.
27.   Kim KB, Kim JH, Kim WC, Kim JH. Three-dimensional 
evaluation of gaps associated with fixed dental prosthe-
ses fabricated with new technologies. J Prosthet Dent. 
2014;112(6):1432-1436.
28.   Zhao XZ, Xu WH, Tang ZH, Wu MJ, Zhu J, Chen S. 
Accuracy of computer-guided implant surgery by a CAD/
CAM and laser scanning technique. Chin J Dent Res. 
2014;17(1):31-36.
Rehabilitation Oncology
Vol. 33, No. 2, 2015
23
29.   Yip E, Smith A, Yoshino M. Volumetric evaluation of facial 
swelling utilizing a 3D range camera. Int J Oral Maxillofac 
Surg. 2004;33(2):179-182.
30.   Kau CH, Richmond S, Zhurov AI, et al. Reliability 
of measuring facial morphology with a 3-dimensional 
laser scanning system. Am J Orthod Dentofacial Orthop. 
2005;128(4):424-430.
31.   Kau CH, Richmond S, Incrapera A, English J, Xia JJ. Three-
dimensional surface acquisition systems for the study of 
facial morphology and their application to maxillofacial 
surgery. Int J Med Robot. 2007;3(2):97-110. 
32.   Harrison JA, Nixon MA, Fright WR, Snape L. Use of hand-
held laser scanning in the assessment of facial swelling: A 
preliminary study. Br J Oral Maxillofac Surg. 2004;42(1):8-
17. 
33.   Ramos SM, O’Donnell LS, Knight G. Edema volume, not 
timing, is the key to success in lymphedema treatment. Am J 
Surg. 1999;178(4):311-315. 
34.   Ort R, Metzler P, Kruse AL, et al. The Reliability of a 
Three-Dimensional Photo System- (3DMDface-) Based 
Evaluation of the Face in Cleft Lip Infants. Plast Surg Int. 
2012;2012:138090.
35.   Rana M, Gellrich NC, Ghassemi A, Gerressen M, Riediger 
D, Modabber A. Three-dimensional evaluation of postopera-
tive swelling after third molar surgery using 2 different cool-
ing therapy methods: a randomized observer-blind prospec-
tive study. J Oral Maxillofac Surg. 2011;69(8):2092-2098.
36.   Rana M, Gellrich NC, Joos U, Piffko J, Kater W. 3D evalu-
ation of postoperative swelling using two different cooling 
methods following orthognathic surgery: a randomised 
observer blind prospective pilot study. Int J Oral Maxillofac 
Surg. 2011;40(7):690-696. 
37.   Rana M, Gellrich NC, von See C, et al. 3D evaluation of post-
operative swelling in treatment of bilateral mandibular frac-
tures using 2 different cooling therapy methods: a random-
ized observer blind prospective study. J Craniomaxillofac 
Surg. 2013;41(1):e17-23.
38.   Maus EA, Tan IC, Rasmussen JC, et al. Near-infrared fluo-
rescence imaging of lymphatics in head and neck lymph-
edema. Head Neck. 2012;34(3):448-453.
39.   Bowskill J, Baldock C, Booth PW. Measuring facial swelling 
using 3D imaging. Med Inform (Lond). 1997;22(2):155-164.
40.   Kau CH, Richmond S, Zhurov A, et al. Use of 3-dimen-
sional surface acquisition to study facial morphology in 5 
populations. Am J Orthod Dentofacial Orthop. 2010;137(4 
Suppl):S56 e1-9.
41.   Mayrovitz HN, Davey S, Shapiro E. Suitability of single 
tissue dielectric constant measurements to assess local tissue 
water in normal and lymphedematous skin. Clin Physiol 
Funct Imaging. 2009;29:123–127.
42.   Jensen MR, Birkballe S, Noerregaard S, Karlsmark T. Validity 
and interobserver agreement of lower extremity local tissue 
water measurements in healthy women using tissue dielectric 
constant. Clin Physiol Funct Imaging. 2012;32:317–322.
43.   Purcell A, Nixon J, Fleming J, McCann A, Porceddu S. 
Measuring head and neck lymphoedema: The “ALOHA” 
trial. Head Neck. 2014 Sep 12.
44.   Mayrovitz HN, Bernal M, Brlit F, Desfor F. Biophysical 
measures of skin tissue water: Variations within and among 
anatomical sites and correlations between measures. Skin Res 
Technol. 2013;19:47-54.
45.   Nixon J, Purcell A, Fleming J, McCann A, Porceddu S. Pilot 
study of an assessment tool for measuring head and neck 
lymphoedema. Br J Community Nurs. 2014 Apr;Suppl S6, 
S8-11. 
46.   Gabka J MT. Measuring techniques and clinical testing of an 
anti-inflammatory agent (tantum). Munch Med Wochenschr. 
1971;13:198-203. 
47.   Schultze-Mosgau S, Schmelzeisen R, Fröhlich JC, et al. Use 
of ibuprofen and methylprednisolone for prevention of pain 
and swelling after removal of impacted third molars. J Oral 
Maxillofac Surg. 1995;53:2-7. 
48.   Stizia J. Volume measurement in lymphoedema treatment: 
Examination of formulae. Eur J Cancer. 1995;4:11-16.
49.   Deltombe T, Jamart J, Recloux S, et al. Reliability and limits 
of agreement of circumferential, water displacement, and 
optoelectronic volumetry in the measurement of upper limb 
lymphedema. Lymphology. 2007;40(1):26-34. 
50.   Ayestaray B, Bekara F, Andreoletti JB. π-Shaped lymphati-
covenular anastomosis for head and neck lymphoedema: 
A preliminary study. J Plast Reconstr Aesthet Surg. 
2013;66(2):201-206.
51.   Liu D, Usmani N, Sloboda RS. Transrectal ultrasound based 
prostate volume determination: Is the frustum algorithm more 
accurate than planimetry? Med Phys. 2013;40(3):031705.
52.   Vokes EE, Kies MS, Haraf DJ, et al. Concomitant chemora-
diotherapy as primary therapy for locoregionally advanced 
head and neck cancer. J Clin Oncol. 2000;18(8):1652-1661.
53.   Guru K, Manoor UK, Supe SS. A comprehensive review 
of head and neck cancer rehabilitation: Physical therapy 
perspectives. Indian J Palliat Care. 2012;18(2):87-97.
54.   Habbous S, Chu KP, Qiu X, et al. The changing incidence 
of human papillomavirus-associated oropharyngeal cancer 
using multiple imputation from 2000 to 2010 at a compre-
hensive cancer centre. Cancer Epidemiol. 2013;37(6):820-
829. 
55.   U.S. Department of Health and Human Services (National 
Institutes of Health National Cancer Institute). Common 
Terminology Criteria for Adverse Events (CTCAE). Version 
4.0. Published: May 28, 2009 (v4.03: June 14, 2010) NIH 
Publication No. 09-5410
56.   Medford AR. Endobronchial ultrasound and extended roles: 
Know thy limitations. Chest. 2013;143(5):1516. 
57.   Haga T, Fukuoka M, Morita M, Cho K, Tatsumi K. 
Indications and complications associated with fiberoptic 
bronchoscopy in very elderly adults. J Ameri Ger Soc. 
2014;62(9):1803-1805. 
Rehabilitation Oncology
Vol. 33, No. 2, 2015
24
Oncology Section EDGE Task Force 
Breast Cancer Outcomes: 
A Systematic Review of Clinical Measures 
of Cardiorespiratory Fitness Tests
Jacqueline S. Drouin, PT, PhD1; G. Stephen Morris, PT, PhD, FACSM2
1Oakland University, School of Health Sciences, Physical Therapy Program, Rochester, MI
2Wingate University, Department of Physical Therapy, Wingate, NC
*Presented as an Oncology Section Educational Session at the American Physical Therapy  
Association’s Combined Sections Meeting in Las Vegas, Nevada; February 2014.
ABSTRACT
Background: Outcomes from standardized exercise tests (SET) 
are used by physical therapists (PTs) to define cardiorespiratory 
fitness (CRF) and develop safe and effective prescriptions for 
aerobic exercise training programs; however, the psychometric 
properties and clinical utility of standard exercise testing has 
not been evaluated in the breast cancer survivor population. 
Objective: To evaluate the psychometric properties, safety, and 
clinical utility of SET and provide informed recommendations for 
their use in clinical practice involving female breast cancer survi-
vors. Design: The study was a systematic review with a measure-
ment focused design. Methods: A comprehensive search was 
performed with a health sciences librarian to identify articles that 
reported psychometric data on SET among women with breast 
cancer.  Criterion articles were evaluated using the Cancer EDGE 
Task Force Outcome Measure Rating Form. Results: Sixty-eight 
articles met initial inclusion criteria, but only 5 were found that 
reported useable psychometric data. Maximal treadmill and cycle 
ergometer tests involving expired gas analysis were valid and 
accurate in this population, but are not safe or efficient for use in 
a clinical setting. Submaximal tests (treadmill, cycle ergometer, 
step, and walk/run tests) that use prediction equations to estimate 
CRF had large errors for minimal detectable differences (3.32-
15.80 ml/kg/min) which approached or exceeded the minimal 
clinically important difference (3.5 ml/kg/min). Furthermore, 
these prediction equations have not been validated in this popu-
lation. Discussion: Limited evidence was found describing the 
psychometric properties of SETs used to determine CRF in breast 
cancer survivors. Available studies suggest clinically efficient 
SETs have moderate to poor concurrent validity with a moderate 
to high standard error; however, standardized exercise testing can 
serve to screen for exercise safety and provide estimates of CRF. 
Exercise prescriptions developed from the outcomes of SET will 
require follow up for potential modifications. Appreciating SET 
limitations enables proper client education and training adjust-
ments needed for safety and exercise efficacy. Conclusions: 
Further understanding of the psychometric properties of SET 
used in the breast cancer survivor population is needed in order 
to make these tests safe, accurate, and clinically useful. 
Key Words: aerobic exercise testing, psychometrics, clinical 
utility, cardiorespiratory fitness, submaximal exercise, maximal 
exercise
INTRODUCTION
Aerobic exercise (AE) is recommended as a safe and effec-
tive method for reducing treatment related side effects and 
promoting cardiorespiratory fitness (CRF) in women with breast 
cancer.1,2 Available evidence suggests that AE may enhance 
cancer treatment efficacy and induce changes in gene expression 
and cancer biology, which might prevent an initial occurrence or 
a reoccurrence of cancer.1-4  Based on this positive evidence for 
health promotion and cancer prevention, it becomes the physical 
therapist’s role to develop safe and effective exercise prescrip-
tions predicated on using accurate and clinically appropriate clin-
ical tests of CRF.1-3,5-8  Current consensus statements recommend 
using standardized exercise tests (SET) according to established 
professional guidelines to determine CRF.2,5-10  However, avail-
able consensus statements acknowledge that the psychometric 
properties of established SETs were developed using non-cancer 
populations; therefore, the accuracy and applicability of CRF 
measures in breast cancer survivors is not known.1,2,9-11
Accurate cardiovascular screening and exercise testing is 
particularly important for breast cancer survivors since cancer 
treatments and adjuvant therapies cause varying amounts of 
acute and/or long-term cardiovascular disorders.1,2,9,12-14 These 
disorders include hypertension, endocardial fibrosis, arrhyth-
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mias, bradycardias, progressive declines in left ventricular func-
tion, and heart failure.13,14 Furthermore, a review of exercise 
testing outcomes from cancer patients found markedly reduced 
CRF levels compared to apparently healthy subjects that were 
attributed to cancer treatments, aging, and sedentary lifestyles.3 
This elevated cardiovascular risk signals the need for appropri-
ate cardiovascular screening, and, when indicated, CRF testing 
to insure that exercise prescriptions are safe and effective.2,9 
Admittedly, there are screening tools such as surveys and walk-
ing tests (6 minute walk test) that are associated with physical 
function and have proven to be clinically useful.5 However, these 
assessments do not measure or readily predict CRF, an outcome 
required for the development of effective exercise prescriptions 
or for screening for disease.  Therefore, these assessments will 
not be evaluated in this paper.2,5  
While a considerable body of evidence exists describing the 
psychometric properties of SET measures of CRF in apparently 
healthy individuals and individuals with cardiovascular disease, 
the psychometric properties of SET used in assessing the CRF of 
breast cancer survivors has not been previously evaluated.1,9,15-42 
Therefore, the purpose of this study was to evaluate the psycho-
metric properties, safety, and clinical utility of SETs in order to 
make informed recommendations regarding their use in clinical 
practice for the purpose of measuring CRF in female survivors 
of breast cancer.  
METHODS
A systematic review using a measurement focused design 
was used to find and evaluate articles that contained data on the 
psychometric properties of SETs used in female survivors of 
breast cancer. The clinical utility and safety of these tests was 
also examined. The literature search was initially performed by 
graduate students in a Doctor of Physical Therapy program with 
guidance from a University Health Sciences Librarian. Criterion 
articles were written in English or had a published abstract 
written in English.  The search began online using CINAHL, 
PEDro, Pubmed (Medline), Cochrane, Science Direct, Hooked on 
Evidence, Web of Science, Scopus, and Sport Discus databases. 
References listed in the selected criterion articles were also evalu-
ated for potential inclusion.  Key search words included: breast 
neoplasm, breast cancer, cancer, SET, aerobic capacity, aerobic 
exercise, aerobic endurance, cardiorespiratory fitness, cardio-
vascular endurance, maximal oxygen consumption, VO2max, 
psychometrics, reliability, validity, standard error of the measure 
(SEM), minimal detectable difference (MDD), minimal clinically 
important difference (MCID), SET, standardized SET, treadmill 
test, cycle ergometer test, walk tests, run tests, and step tests.
The psychometric properties, safety, and clinical utility of 
the SETs were reviewed using the Cancer EDGE (Evidence 
Database to Guide Effectiveness) Task Force Outcome Measure 
Rating Form.  This evaluation tool uses a format adapted from 
the Section on Research EDGE Form and recommended by 
the American Physical Therapy Association EDGE task force. 
Although this tool recommends limiting the search to articles 
published in the previous 10 years, the SET psychometric studies 
began in the 1930s, so no date limitation was applied to articles 
in the search.  The evaluators were two physical therapists with 
advanced academic degrees in exercise physiology, research 
design, and statistics.  The evaluations ratings used were the 
categories from the Breast Cancer EDGE tool seen in Table 1. 
When evaluation ratings did not agree, the authors reviewed the 
evidence to achieve consensus.  
Criterion articles were from original studies that presented 
the psychometrics, safety and clinical utility of SETs used in the 
breast cancer population. Articles were also included if the data 
provided could be used to calculate concurrent validity, test-retest 
reliability, SEM, MDD, and MCID. Articles were removed that 
did not include data from a SET, did not clearly explain the type 
of SET performed, or that used functional assessments or reported 
fitness derived from surveys or self-reports. Systematic reviews, 
commentaries or recommendations, or practice guidelines were 
not reviewed; however, reference lists from these sources were 
examined for potential references.
RESULTS
Initially, 3837 articles were identified through key word 
searches of online data bases. Following removal of duplicates 
(n = 1803) and non-criterion articles through title and abstract 
Table 1. Breast Cancer EDGE* Evaluation Categories
4 Highly Recommend Highly Recommend; the outcome has excellent psychometric properties and clinical utility;  the measure has been used in research on individuals with or post breast cancer.
3 Recommend Recommend; the outcome measure has good psychometric properties and good clinical utility; no published evidence that the measure has been applied to research on individuals with or post breast cancer.
2A Unable to RecommendAt this time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure; 
the measure has been used in research on individuals with or post breast cancer.
2B Unable to Recommend At this time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure; 
no published evidence that the measure has been applied to research on individuals with or post breast cancer.
1 Do not Recommend Poor psychometrics &/or poor clinical utility (time, equipment, cost, etc.).
*  Cancer EDGE (Evidence Database to Guide Effectiveness) Task Force Outcome Measure Rating Form; adapted from the Section on Research EDGE Form recom-
mended by the APTA EDGE Task Force.
Rehabilitation Oncology
Vol. 33, No. 2, 2015
26
reviews (n = 1984), and then adding 18 articles from reference 
checks, 68 articles were selected for review (Figure 1). Of these 
articles, 5 were identified that included psychometric data or data 
that could be used to calculate psychometric values in the breast 
cancer population. Two studies were also found that examined 
the safety of exercise testing conducted in female breast cancer 
survivors.
Evidence from sports medicine and science journals recom-
mend that concurrent validity and test-retest reliability are 
the psychometrics most appropriate for evaluating SETs.15,43, 
44  Concurrent validity is the degree to which SET measures 
agree with those obtained using gold standard measures.17,43,44 
The statistical analyses used to determine concurrent validity 
are Intraclass Correlation Coefficients [ICC (model 2, 1 or 2, k)] 
and Coefficients of Variation (COV).15,44,45 The ICC provides a 
measure of the agreement between two or more tests expressed 
as values between 0 and 1.0.20,44 Higher values represent better 
agreement; however, the values are difficult to interpret and there 
is controversy regarding the level viewed as acceptable.15,43-45 
Some older articles suggest that correlation coefficients of .75 
or higher are excellent, while more current reviews indicate that 
the ICC must be .90 or higher for a test to be useful in clinical 
practice and research.15,43,45,46 Prior studies have also used the 
Pearson Product Moment (r) to determine associations between 
tests; however, this statistic is not the preferred method as it is 
not able to account for systematic error and it overestimates asso-
ciations when samples are small.15,43-45 Based on the evidence, a 
rating of excellent in this review required a value of .90 or above. 
Measures of concurrent validity for various SET appear in Table 
3 and Table 4; when the ICC was not available, the Pearson 
Product Moments was instead reported.
The COV presents the typical error as the percent change 
in the mean.15,45 The COV is a straightforward, dimensionless 
measure that enables comparisons of scores from different types 
of subjects (males vs females) as well as different tests (tread-
mill vs cycle ergometer). As such, the COV is easier to interpret 
and may be more useful in clinical and research settings.15 The 
lower the COV value, the higher the agreement with the gold 
standard measure; however, some authors suggest that 5% or 
higher represents poor reliability and this standard was used in 
the current evaluation.20 The COV values derived from sport and 
performance tests appear in Table 3 and Table 4. When the COV 
was not available, the percent difference between the tests was 
reported.
Test-retest reliability provides a measure of the precision or 
reproducibility of SET measures taken over time and it can be 
used to assess the exercise device, the test protocol, the subject, 
as well as the raters.15  The recommended statistics again are the 
ICC (model 3, 1) and the COV as described previously.46
Standard errors of a measure are clinically useful for deter-
mining both concurrent validity and test-retest reliability.44 Like 
the COV, the SEM is a calculation of the typical error and it is 
robust to small samples.15,44 The SEM is clinically useful as it 
is reported in the same units as the test data.15,44 For example, 
an SEM of 0.05 ml/kg/min for an SET for an MCID of 3.5 ml/
kg/min would be considered excellent agreement. However, an 
SEM for an SET that approaches or exceeds the MCID would 
be invalid and unreliable for measuring CRF and subsequently 
developing safe and effective exercise prescription intensities. 
The SEM is also used to calculate the MDD which allows clini-
cians to determine whether changes in a patient’s score were 
real or simply within the error of the measure; therefore, lower 
MDD values were associated with higher levels of accuracy.43 
The values for test-retest reliability appear in Table 3 and Table 
4.  When the SEM was not reported, the standard error of the 
estimate (SEE) was provided.
Maximal Exercise Tests
Maximal SETs complete with gas analysis can be performed 
using a treadmill or a cycle ergometer.2 Both methods require the 
subject to perform a maximal physical effort and analyze expired 
gases for O2 and CO2 content which is then used to calculate 
maximal oxygen consumption or VO2max.
2 The criteria defining 
a maximal CRF SET includes plateauing of the heart rate and/
or oxygen consumption despite increases in the workload and a 
respiratory exchange ratio (CO2 released/O2 consumed) of 1.15 or 
greater.17-19 However, not all individuals are able to reach maxi-
mal cardiorespiratory levels due to musculoskeletal, neuromus-
cular or other physical limitations.2,6-8 It is also not safe for many 
individuals to perform maximal exercise, particularly if they have 
known or suspected cardiovascular conditions.2,6-8
Maximal oxygen consumption is measured in milliliters 
per kilogram body weight per minute (ml/kg/min) which is a 
standardized value that allows for comparisons between indi-
viduals or across time for a single individual which can be used 
to asses changes in CRF.17-19  The MCID derived from studies in 
Figure 1. Flow of literature search process for psychometric 
measures.
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Table 2. Standardized Exercise Test Outcomes: EDGE Task Force Rating & Clinical Utility
Standardized 
Exercise Test
Task Force 
Rating Psychometrics Clinical Utility and Safety
Maximal Tests with Oxygen Analysis
Treadmill
1 
Do not 
Recommend
·	 Used in 14 breast cancer research intervention studies  
·	 Psychometrics for valid CRF measures found in one breast 
cancer study  
·	 Excellent validity and reliability from non-breast cancer 
studies 
·	 Very expensive
·	 Time intensive (45-60 min)
·	 Specialized training
·	 Requires 2 clinicians to perform
·	 Often requires physician onsite
·	 Contraindicated in national practice standards due to 
safety risks of performing maximal exercise
Cycle 
Ergometer
1
Do not 
Recommend
·	 Used in 15 breast cancer intervention studies  
·	 Psychometrics found adequate for test-retest reliability in 
one breast cancer study
·	 Psychometrics from non-breast cancer studies were poor to 
excellent for concurrent validity and moderate to poor for 
clinical relevance as MDD may exceed MDIC 
·	 Very expensive
·	 Time intensive (45-60 min)
·	 Specialized training
·	 Requires 2 clinicians to perform
·	 Often requires physician onsite
·	 Contraindicated in national practice standards due to 
safety risks of performing maximal exercise
Submaximal Tests with Prediction Equations 
Treadmill
2A 
Unable to 
Recommend
At this time
·	 Used in 7 breast cancer research studies 
·	 Prediction equations for heart rate maximum to determine 
submaximal test endpoints and CRF found invalid in 2 
breast cancer studies 
·	 Psychometrics not assessed in breast cancer research stud-
ies
·	 Psychometrics from non-breast cancer studies are fair to 
good for concurrent validity but standard errors were high 
and the MDD exceeded the MDIC contributing to poor 
reliability. 
·	 Low cost and easy to administer
·	 Less time to administer (20-30 minutes)
·	 Requires 2 clinicians: one performs test and other onsite 
for safety concerns
·	 Requires following standardized protocol and accurate 
heart rate measures
·	 Safe to administer with proper pre-screening. Monitoring 
and patient instructions
Cycle 
Ergometer
2A 
Unable to 
Recommend
At this time
·	 Used in 5 breast cancer research studies 
·	 Psychometrics poor for sensitivity and concurrent valid-
ity with VO2max cycle ergometer tests in 2 breast cancer 
studies 
·	 Psychometrics adequate for test-retest reliability in one 
breast cancer study
·	 Prediction equations for heart rate maximum to determine 
submaximal test endpoints and CRF were invalid in 2 
breast cancer studies 
·	 Low cost, portable, and easy to administer
·	 Less time to administer (20-30 minutes)
·	 Requires 2 clinicians: one performs test and other onsite 
for safety concerns
·	 Requires following standardized protocol and accurate 
heart rate measures
·	 Safe to administer with proper pre-screening. Monitoring 
and patient instructions
Field Tests
12-Min Run 1 
Do Not 
Recommend
·	 Not used in breast cancer research 
·	 MDD exceeds MCID 
·	 Validity of CRF prediction equations not assessed in breast 
cancer research
·	 Easy to administer 
·	 Low cost
·	 Can assess multiple subjects at same time 
·	 Contraindicated due to safety as vital signs not moni-
tored during test and there is potential to perform a 
maximal test
12-Min Walk 2A 
Unable to 
Recommend
At this time
·	 Used in 5 breast cancer research studies
·	 MDD and SEM not defined 
·	 Reliability and Validity not determined for breast cancer 
survivors
·	 Validity of CRF prediction equations not assessed in breast 
cancer research
·	 Easy to administer
·	 Low cost
·	 Can assess multiple subjects at same time 
·	 Contraindicated due to safety as subjects vital signs are 
not monitored during testing and there is potential to 
perform a maximal test
1-Mile Walk 2A  
Unable to 
Recommend
At this time
·	 Used in breast cancer research 
·	 MDD and SEM not defined
·	 Validity of CRF prediction equations not assessed in breast 
cancer research
·	 Easy to administer
·	 Can assess multiple subjects at same time 
·	 Requires vital signs monitoring for safety as potential to 
perform a maximal test
Step Test
(Canadian 
Aerobic 
Fitness Test 
protocol)
2A
Unable to 
Recommend
At this time
·	 Used in one breast cancer research study
·	 Psychometrics for not assessed in breast cancer research 
studies 
·	 Validity of CRF prediction equations not assessed in breast 
cancer research
·	 Standard errors were high and the MDD exceeded the 
MDIC contributing to poor reliability. 
·	 Easy to administer
·	 Low cost
·	 Can assess multiple subjects at same time 
·	 Requires fixed step height and cadence 
·	 Safety issues related to balance and falls, and vital signs 
not monitored during test leading to potential to perform 
a maximal test
·	 Requires high MET levels not appropriate for sedentary 
or low fitness individuals
Abbreviations: CRF, cardiorespiratory fitness; MDD, minimal detectable difference; MCID, minimal clinically important difference; SEM, standard of measurement
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apparently healthy people is one metabolic equivalent (MET), 
which is equal to 3.5 ml/kg/min of oxygen.2,42,43 The 3.5 ml/kg/
min definition for the MET is lower in women than in men and 
it also gradually decreases with aging; however, the validity of 
the MCID measure has not been determined among breast cancer 
survivors.2,42,43
VO2max Treadmill Tests
Extensive study and scientific evidence from other popu-
lations supports the VO2max treadmill SETs as the gold stan-
dard for accurate measurement of CRF.2,9,15,17-21 These tests 
are performed on a motor-driven treadmill with expired gases 
analyzed for O2 and CO2 content.  Administration time is about 
45 to 60 minutes including time for set-up, preparation, warm-up, 
testing, and cool-down.2,9,15 There are a number of standardized 
protocols available for use in different populations, all involving 
a step-wise, progressive increase in exercise intensity until the 
criteria demonstrating maximal exertion the maximal criteria has 
been achieved.2,17-19  
Twenty-three articles were initially found that used VO2max 
treadmill testing to determine the CRF of breast cancer survi-
vors; however, several of these papers were secondary analysis 
of original data sets resulting in only 14 original sets of exercise 
test data.47-69 Unfortunately, the majority of the studies did not 
Table 3. Concurrent Validity
Exercise Test Population Assessed Concurrent Validitya
COV or Percent Difference 
between Meansb
Standard Error  
of the Measurec 
ml/kg/min
Minimal Detectable 
Differenced
ml/kg/min
Maximal Tests with Oxygen Analysis
Treadmill 
Test Healthy Males & Females, Athletes
17-19 ICC = .97
<1.5-2.0%
(with Douglas Bag) ± 0.05-0.06 ± 0.15 - 0.17 
Women with Breast Cancer Not found Not found Not found Not found
Cycle 
Ergometer Healthy Males & Females, Athletes
16-19 R2 = .60-96 COV = 1.5 (1.1-2.0) - 0.7 to 1.3
SEE = - 4.5
1.9-3.6
Women with Breast Cancer55 
(Reported as raw difference and percent) Not found
- 16.7%B
(-4.8 ml/kg/min) Not found Not found
Submaximal Tests used with Prediction Equations
Treadmill 
Test Healthy Males & Females, Athletes
17-19, R2 =.76-.88 Not found ± 3.4 – 5.3 9.4-14.7
Women with Breast Cancer n/a n/a n/a n/a
Cycle 
Ergometer
Healthy Males & Females, Athletes, 
Individuals with Cancer16-19, 27, 34, 71 
R2 =.61-.96
R2 = .50-.62 10
9.4 - 16.6%
-9.0%71
(Compared to V̊O2max 
cycle ergometer)
SEE = 3.12-4.23 
11.6-15.8
Women with Breast Cancer Not found Not found Not found Not found
12 Minute 
Run Healthy Males & Females, Athletes
17-19, 27 R2 = .02-.85
(not a typo) n/a n/a n/a
Women with Breast Cancer Not found Not found Not found Not found
12 Minute 
Walk Individuals with Heart and Lung Disease 
27, 37 R2 = .24-.27 n/a n/a n/a
Women with Breast Cancer Not found Not found Not found Not found
1 Mile 
Walk Healthy Males & Females
16, 34, 38-40 ICC=.96-.97
R2 = .62-86 Not found
SEE =  5.68 
SEE 0.325 L/min Not found
Women with Breast Cancer Not found Not found Not found Not found
Step 
Test Healthy Males & Females, Athletes
17-19, 33-35 R2 = .62-.85 -3.8% SEM = 4.08
SEE = 2.9–4.1
11.3
Women with Breast Cancer Not found Not found Not found Not found
a  The Pearson Product Moment (r) was reported when Intraclass Correlation Coefficients (ICC) were not found.
b  Percent difference was reported when the Coefficient of Variation was not found.
c  Standard Error of the Estimate (SEE) was reported when Standard Error of the Measure (SEM) was not found.
d  Minimal Detectable Difference (MDD) at 95% Confidence Level.
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explain whether the subjects’ performance met the criteria for 
maximal exertion and many did not report oxygen consumption 
in ml/kg/min.  These reporting problems have been cited in prior 
reviews as they prevent scientific interpretation of the results 
as well as calculation of psychometric measures.9,10 Only one 
article provided data sufficient to demonstrate that the subjects 
met the VO2max criteria, which suggests that this mode of SET 
is valid in this population.57 Although the psychometric proper-
ties for VO2max treadmill tests undertaken by healthy popula-
tions and individuals with heart disease are available, no studies 
were found that presented correlation coefficients for test-retest 
reliability, COV, SEM, MDD, or MCID specifically for VO2max 
treadmill tests performed by breast cancer survivors.
VO2max treadmill tests are the recommended method 
for evaluating CRF because of the accuracy of its measure-
ments.2,9,15,17-21 Despite its status as the gold standard measure, 
VO2max treadmill testing is not recommended in national stan-
dards written for exercise testing in the clinic.2,5-8,19 These tests 
are time-consuming, expensive to perform, and require special-
ized and costly equipment.2,5-8 These tests also require advanced 
training for the test administrators and the presence of at least two 
clinic staff members for safety during testing.2,5-8 Depending on 
the subject’s physical status, a physician may be required to be 
on-site during testing.2,5-8 Most importantly, national guidelines 
for clinical practice do not deem maximal exercise testing as 
being safe for many individuals when performed in the clini-
cal setting.2,5-8 Therefore, based on clinical efficiency and safety 
concerns, the EDGE rating for maximal treadmill tests with 
oxygen analysis was: “1 - Do not Recommend.”
Table 4. Test-retest Reliability: Standardized Exercise Tests 
Exercise Test Population Test-Retest Correlationa
Percent 
Differenceb 
Standard Error of 
the Measurec 
ml/kg/min
Minimal Detectable 
Difference
Maximal Tests with Oxygen Analysis
Treadmill 
Test Healthy Males & Females
16-20,25,26, 107 ICC = .95
2.0-5.0%
COV = 0.9D
2.58107 Not found
Women with Breast Cancer Not found Not found Not found Not found
Cycle 
Ergometer Healthy Males & Females, Athletes
17-20 R2 = .74-94 COV = 0.9d - 8.1% n/a
Women with Breast Cancer Not found Not found Not found Not found
Submaximal Tests with Prediction Equations
Treadmill 
Test Healthy Males & Females, Athletes
17-19, 34 R2 = .85 Not found Not found Not found
Women with Breast Cancer Not found Not found Not found Not found
Cycle 
Ergometer
Healthy Males & Females, Athletes, individuals 
with Cancer17-19, 27, 71.96
ICC = .95-.9917-19, 97
ICC = .87371
Not found 1.5
17-19, 27
-.02 ± 3.2996, e
3.32
Women with Breast Cancer Not found Not found Not found Not found
Step 
Test Healthy Males & Females
36  R2 = .62 Not found Not found Not found
Women with Breast Cancer Not found Not found Not found Not found
12 Minute 
Run Healthy Males & Females
27 F = .96 Not found 1.6 4.54
Women with Breast Cancer Not found Not found Not found Not found
12 Minute 
Walk Individuals with Heart and Lung Disease 
37 ICC=.96-.99 COV= 4.2-8.6 Not found Not Found
Women with Breast Cancer Not found Not found Not found Not found
1 Mile 
Walk Healthy Males & Females
40 ICC = .97 Not found Not found Not found
Women with Breast Cancer Not found Not found Not found Not found
a  When Intraclass Correlation Coefficients (ICC) were not found; R2 was reported.
b  Percent difference was reported when the Coefficient of Variation was not found.
c  Standard Error of the Estimate (SEE) was reported when Standard Error of the Measure (SEM) was not found.
d  Calculated for peak VO2 measures, not always with oxygen analysis.
e  Limits of Agreement.
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VO2max Cycle Ergometer Tests
Maximal oxygen consumption testing can also be performed 
using a bicycle ergometer.  As with maximal treadmill exercise 
testing, VO2max cycle ergometer tests require subjects to perform 
a maximal physical effort to criterion endpoints and measures 
CRF (VO2/ml/kg).
2  A mechanically-braked cycle ergometer 
provides standardized pedal resistance that can be used in 
various single and multi-stage protocols.2 Since the subject is 
seated, the test can be used for individuals who are unable or are 
unsafe to walk on a treadmill.2 The test takes approximately 45 
to 60 minutes to administer.2,34 In studies on apparently healthy 
subjects, test-retest reliability can be good if standardized testing 
guidelines are followed.2,15,16 However, cycle ergometer measures 
are approximately 10% lower than gold standard measures, 
which reduces the test’s concurrent validity.2,15,20,28,46
Fifteen studies were found that used VO2max cycle 
ergometer tests to determine the CRF levels of female breast 
cancer survivors.55,70-83 Only one of these studies presented the 
psychometric properties of maximal cycle ergometer SETs 
among breast cancer survivors.  Dolan et al found poor concurrent 
validity between VO2max cycle ergometer measures and VO2max 
treadmill measures among 12 breast cancer survivors.55 The cycle 
ergometer measures were 4.8 ml/kg/min lower than measures 
obtained from the treadmill test and this difference exceeded the 
MCID for CRF measures.55
Studies from other populations found acceptable test-retest 
reliability measures; however, studies from women with breast 
cancer and other populations found the concurrent validity with 
gold standard measures was poor.16.34,55 In addition, similar to 
VO2max treadmill tests, VO2max cycle ergometer tests are not 
recommended in national standards for clinical exercise testing 
due to the poor clinical efficiency and safety concerns for 
patients.2,5-8,19  Therefore, the EDGE rating for VO2max cycle 
ergometer tests was: “1 - Do not Recommend.”
Submaximal Exercise Tests
Because of the safety concerns associated with maximal 
exercise testing, exercise testing protocols requiring submaximal 
exertional efforts are available and widely used clinically. These 
tests do not involve analysis of expired gases and are stopped 
at a predetermined exertional level. Resulting physiologic data 
(heart rate, time) as well as anthropometric data are entered into 
derived equations or prediction equations which generate esti-
mates of VO2max.
2,34 Therefore, subject preparation, precise heart 
rate measurement, and valid prediction equations are required 
for estimates of CRF to be accurate.2,28,34,39,41 Since subjects do 
not perform a maximal physical effort, submaximal tests offer a 
safer alternative to maximal testing as long as proper screening, 
monitoring, and patient instructions are provided.2,5-8,34 Also, the 
costs associated with a metabolic cart and specialty training are 
not required since oxygen analysis is not performed.
Submaximal Treadmill Tests
Submaximal treadmill testing protocols often use the same 
protocols as VO2max treadmill tests.
2,28,34 Testing takes approxi-
mately 20 to 30 minutes and typically the test ends when individ-
uals reach 70% of their heart rate reserve, 85% of their predicted 
maximal heart rate, or they develop adverse signs and symp-
toms.2,28,34 Eight published articles were found that appeared to 
consist of 7 original data sets derived from female breast cancer 
survivors who had undergone submaximal treadmill testing.84-92 
The tests primarily tracked changes in CRF following subject 
participation in exercise training interventions.  Studies on non-
breast cancer subjects found the SEM could exceed the MCID 
for concurrent validity and test-retest reliability if standardized 
testing protocols were not followed.2,34,41 Two studies examining 
survivors of breast cancer found that current equations used to 
estimate maximum heart rate overestimated maximal heart rate 
by approximately 10 beats per minute.57,58 One of these studies 
also suggested that reported ratings of perceived exertion were 
significantly lower than predicted values for specified exer-
cise intensities.57 A study by Evans et al examined differences 
in heart rate, ratings of perceived exertion, and blood lactate 
concentrations between women with breast cancer and appar-
ently healthy women at various exertional intensities.92 Results 
demonstrated that these physiologic measures were similar 
between these groups at low to moderate exertional levels, but at 
70% of VO2max blood lactate levels were significantly different, 
suggesting differences existed in the physiological responses of 
survivors of breast cancer to moderate to high intensity exercise. 
In turn, these findings suggest that a better understanding of these 
differences is needed in order to write safe, appropriate, and 
effective exercise prescriptions.
In summary, submaximal treadmill tests have been used 
in breast cancer studies to provide an estimate of CRF and are 
relatively easy to administer and safe with proper screening 
and monitoring.1,2,11,83  These tests offer improved clinical utility 
relative to time spent in testing, equipment costs, and specialty 
training.  However, psychometric measures may be unacceptable 
and the equations used to predict CRF require further validation. 
Therefore, the EDGE rating for submaximal treadmill tests was: 
“2A - Unable to Recommend at this time.”
Submaximal Cycle Ergometer Tests
Submaximal cycle ergometer tests are also available and 
utilize prediction equations to estimate CRF and to determine test 
endpoints.2,16,28,34 Therefore, the costs of a gas analysis equipment 
and specialty training are eliminated. Because these are submaxi-
mal tests, subjects are not required to perform a maximal effort; 
therefore, with proper screening, the tests are safer to perform.2,34 
The test is clinically efficient and takes approximately 20 to 30 
minutes to administer.2,16,28,34
Five studies were found that used submaximal cycle ergom-
eter tests in breast cancer research and two studies measured 
psychometric properties.71,78,93-95 Debacker et al compared 
measures from a submaximal cycle ergometer test to a maximal 
short exercise capacity test (steep ramp test) and a VO2max cycle 
ergometer test to detect changes in CRF after an 18-week train-
ing program among male and female cancer survivors.71 The 
submaximal cycle ergometer tests proved invalid for detecting 
changes in CRF following exercise training compared with the 
two maximal tests (r = .71 to .79). The study did calculate test-
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retest reliability for the submaximal cycle ergometer test in this 
population as good as ICC = .873 (CI95 =.72 to .95).  A subsequent 
study by May et al also examined the sensitivity of submaximal 
cycle ergometer tests to detect changes in CRF following train-
ing in subjects with cancer.78  The study found a modest, but poor 
correlation [r = -.51 (p  = .006)] for the sensitivity of submaxi-
mal cycle ergometer measures compared with VO2max cycle 
measures. The subjects in both the Debacker et al and the May et 
al studies had a variety of cancer diagnoses and data was reported 
in aggregate, so results specific for female breast cancer survivors 
were not available.  
One additional study was found that examined test-retest reli-
ability for the submaximal cycle ergometer test with oxygen anal-
ysis in subjects with lymphohematopoietic cancers.96  Although 
this study did not include women with breast cancer, it did 
provide psychometrics for test-retest reliability for a submaximal 
cycle ergometer test of ICC = .96 among individuals with cancer 
which was excellent.  Limits of agreement (LOA) and random 
error measures were also provided as LOA = -.02 ± 3.29 which 
can exceed the MCID for CRF measures.  
Submaximal cycle ergometer tests have been used in breast 
cancer research and they appear to offer improved safety with 
proper screening. The tests also have good clinical utility rela-
tive to equipment cost and administration time.74,83 There is 
also some psychometric evidence collected from women with 
breast cancer.71, 78 Currently available evidence suggests test-
retest reliability for submaximal cycle ergometers is moderate to 
good; however, standard errors continue to be large which may 
contribute to inappropriate categorization of CRF and subsequent 
errors in the exercise prescription intensities.71,78 Both studies also 
suggest that submaximal cycle ergometer tests lack sensitivity to 
identify changes in CRF following training.71,78 Finally, similar 
to submaximal treadmill tests, ratings of perceived exertion and 
prediction equations for test endpoints and CRF have not been 
validated in the breast cancer population. The EDGE rating 
for the submaximal cycle ergometer test was: “2A - Unable to 
Recommend at this Time.”
Field Tests
Field tests also use derived prediction equations to estimate 
CRF using distance, time, or heart rate responses during walking 
or running tests.2,34 Common field tests include the 12 minute 
walk (12-MWT) or run test, the 1.5 mile walk or run test, and the 
1 mile walk test (1-MWT).2,34,38-40 Field tests are easy to admin-
ister, require little equipment, and often can be used to assess 
multiple individuals simultaneously.2,34 The prediction equations 
that estimate CRF from field test outcomes may require factors 
such as age, gender, weight, and training status to improve the 
estimate’s accuracy; however, the prediction equations must be 
validated within each specific population.2,34,38-40 Field tests suffer 
from the fact that vital signs are not monitored during testing 
and individuals with low fitness levels or cardiovascular risk 
may perform a maximal physical effort and compromise their 
safety.2,34  
Twelve Minute Walk/Run Tests
The 12 minute walk and run tests use prediction equations 
based on distance covered in 12 minutes to estimate CRF.2,34 
The objective of 12 min walk and run tests is to cover as much 
distance as possible within the allotted time. Cooper’s 12 minute 
run test was the original assessment tool of this type and it was 
developed using young athletic males.2,34  The 12-MWT is a 
modification of Cooper’s run test; however, the walk test may be 
more appropriate for individuals in the rehabilitation setting.2, 34 
Both tests require a stop-watch or clock and a track with marked 
distances. The test-retest reliability for the 12 minute run test 
was reported as r =.90; however, concurrent validity is not clear 
as values range from r = .13 to .90.2,27,34 Since vital signs are not 
monitored during either test, there are safety concerns for individ-
uals with low fitness or cardiovascular risk factors.2,34 There were 
no articles found that validated the CRF prediction equations in 
breast cancer survivors for either of these tests.
No articles were found that used or validated the 12 minute 
run test in breast cancer survivors. The test is also not recom-
mended for individuals with low fitness, cardiovascular risks, 
or in rehabilitation due to safety concerns. Therefore the EDGE 
rating for the 12 minute run test was: “1 – Do not recommend.”
Five articles were found that used the 12-MWT among breast 
cancer survivors.97-101 The studies all referenced the concurrent 
validity and reliability given for the Cooper 12 minute run test, 
but no articles were found that provided psychometrics for the 
12-MWT administered specifically to breast cancer survivors. 
Since there were no psychometric measures or validated predic-
tion equations for the 12-MWT for use with breast cancer survi-
vors and there are safety concerns related to lack of vital signs 
measurement during testing, the EDGE rating for the 12-MWT 
was: “2A - Unable to Recommend at this Time.”
Distance Walk or Run Tests
The 1-MWT, also known as the Rockport Test, predicts CRF 
fitness categories based on the heart rate obtained at or near the 
end of the test.  This test has been used and reported with walking 
and running and has variations in the distances covered including: 
1.0, 1.5, and 2.0 miles. This test appears to have good concurrent 
validity (ICC = .96-.97) and test-retest agreement values (ICC 
= .97) from other populations, although the SEM is not known. 
The prediction equations derived from this test have not been 
validated among breast cancer survivors.  The test may also have 
issues with safety since since again vital signs are not monitored 
during testing.
Two studies were found that used a 1-MWT in breast cancer 
research, although it appeared that the same data set was used for 
the two different analyses.80,104 The test appears to be clinically 
efficient and may be safe for the breast cancer survivors as long 
as subjects are appropriately screened and vital signs are moni-
tored during testing for safety.1,9,34 The test appears to have good 
concurrent validity and test-retest reliability in other populations; 
however, the prediction equations have not been validated for 
use with breast cancer survivors.  The 1-MWT may become a 
clinically useful assessment; however, at the present time, the 
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evaluators did not feel there was adequate evidence available to 
recommend this test.  Therefore, the EDGE rating for the 1-MWT 
was “2A - Unable to Recommend at this Time.”
Step Tests
Step tests estimate CRF through equations that use the heart 
rate response to stepping up and down stairs of a fixed height at 
a fixed stepping rate.2,34 The test requires a criterion height step, 
a metronome or audio cadence signal, and a stopwatch. The text 
takes only a few minutes to perform and several subjects can be 
tested at the same time. The test has good clinical utility since it 
is low cost, requires minimal equipment, and is time-efficient. 
Based on data from other populations, the test has moderate to 
weak agreement with gold standard measures and the test-retest 
reliability exceeds the MCID for low accuracy. The test also 
requires energy expenditures of 7-9 METs, rendering it unsafe 
or not possible for individuals with low fitness or cardiovas-
cular disease to perform.2,34,103 The requirement for stepping 
up and down from a specific height poses performance and 
safety concerns for individuals with musculoskeletal, balance, or 
sensory deficits (peripheral neuropathies) in the lower extremi-
ties.  
One study was found that used a step test [Canadian Aerobic 
Fitness Test (CAFT)] to assess CRF of women with breast 
cancer.102 However, no studies were found which presented the 
psychometric properties of step tests or the CAFT in the breast 
cancer survivor population. The test is safe and clinically efficient 
as long as individuals have a high fitness level, but issues with 
accuracy and safety are a concern in the clinical setting. The 
EDGE rating for the step test was: “2A - Unable to Recommend 
at this Time.”
Exercise Testing and Training Safety
Two articles were found that examined the safety of maximal 
cycle ergometer tests for women with breast cancer. Hornsby et al 
found 12 non-significant ECG changes and 3 non-life threatening 
events during 30 VO2max cycle ergometer tests performed by 10 
women in treatment for breast cancer.74 Jones et al examined the 
safety of VO2max cycle ergometer test among 85 individuals with 
advanced cancers, 39 of whom had metastatic breast cancer.83 
One female subject experienced a significant ECG change 
(ST segment depression) and another experienced an exercise-
induced, asymptomatic right bundle branch block that normalized 
at test termination. Both studies concluded that exercise testing 
is relatively safe and effective for use in research among female 
breast cancer survivors as long as proper screening, and vital 
signs and ECG monitoring are performed. A few additional arti-
cles and reviews provided summary information based on the use 
of exercise testing performed in research on breast cancer survi-
vors that supported the safety of exercise testing and training as 
long as standardized screening and monitoring is performed.1,70,78
DISCUSSION
The purpose of this study was to evaluate the psychometric 
properties, safety, and clinical utility of tests used to assess or 
estimate CRF for their use in clinical practice among women 
with breast cancer. A systematic literature search yielded only 
5 studies that assessed psychometric values for CRF measures 
among women with breast cancer and two studies that assessed 
safety.55-58,71,74,78,83
Three studies were found that reported the psychometric 
measures derived from maximal tests and involving analysis 
of expired gases. One study provided evidence that women 
undergoing treatment for breast cancer could meet the criteria 
for performing valid VO2max treadmill tests.
57 This study and a 
follow up study also found that currently used heart rate predic-
tion equations significantly overestimate maximal heart rates for 
women with breast cancer.57,5  In the event that maximal heart 
rates are being overestimated with current equations, exercise 
test endpoints and exercise prescriptions would be calculated 
at higher than desirable intensities and pose safety and motiva-
tion concerns. A third study estimated the concurrent validity of 
VO2max cycle ergometer tests and found CRF measures were 
4.8 ml/kg/min lower, which exceeded the MCID of 3.5 ml/kg/
min. This suggests that individuals would be incorrectly placed in 
lower CRF fitness categories and subsequently receive less effec-
tive exercise prescriptions, particularly if they were not exercis-
ing on a cycle ergometer.
Two studies were found that examined submaximal cycle 
ergometer psychometric measures.71,78 Both studies found that 
submaximal cycle ergometer measures were not sensitive to 
detect changes in CRF following an exercise training interven-
tion.71,78 Additionally, one of the studies did find that submaximal 
cycle ergometer test-retest reliability (ICC = .873) was accept-
able, although lower than values reported for apparently healthy 
subjects (ICC = .95-.99).  
This evaluation found very few studies on the psychometric 
properties of CRF measures among women with breast cancer. 
Furthermore, the psychometrics determined from other popula-
tions for tests with good clinical utility were not sufficiently valid 
or reliable.2,16,34,38,40  Therefore, the highest ratings given in this 
evaluation were: “2A - Unable to recommend at this time.”  This 
rating was given to submaximal treadmill and cycle ergometer 
tests, step tests, the 12-MWT, and the 1-MWT.  While the step 
test may not be appropriate for all individuals, the decision to use 
this test should be made by the clinician based on the individual’s 
evaluation results.  Three of the CRF measures received a rating 
of: “1 – Do not recommend.”  The CRF measures that received 
this rating were the VO2max cycle ergometer and treadmill tests, 
due to poor clinical utility and safety concerns based on national 
guidelines.2,5-8  The 12 minute run test also received a rating of 
“1 – Do not recommend,” since it had not been used in research 
studies involving breast cancer survivors, the psychometrics were 
not adequately determined, and due to safety concerns related to 
the potential to perform a maximal test.2,27,34 
Despite the current ratings presented in this evaluation, 
physical therapist practice guidelines stipulate that some form of 
screening or testing be performed prior to developing activity or 
exercise prescriptions.5 Recommendations from other studies and 
reviews suggest that current guidelines developed for apparently 
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healthy subjects and individuals with cardiovascular and pulmo-
nary conditions be used to guide exercise screening and testing 
among individuals with cancer; however, the articles also recom-
mend further research to support the validity, efficacy, and safety 
of CRF testing  for women with breast cancer.1,9,11,74,83  
In terms of clinical practice, following professional guide-
lines for screening and testing will promote as much as currently 
possible, valid, reliable and safe results.9 However, in the event 
that exercise screening or testing protocols require modifications 
to accommodate the patient’s needs or preferences, these adapta-
tions should be noted in the physical therapy report to enable 
accurate test replication and interpretation at a subsequent time.5 
To promote accuracy and safety, clinicians need to appreciate 
screening and testing risks and be aware of the individual’s health 
status and possible cancer treatment co-morbidities. Some of 
these conditions include: pain, nausea, dehydration, lymphedema 
or shoulder pathology, breathing or movement difficulties related 
to the surgery, reconstruction methods that may compromise core-
stability and place the individual at risk for back pain, cognitive 
deficits (chemo-brain) or depression that may affect adherence to 
exercise or judgment, a prior sedentary lifestyle, cardiovascular 
toxicity from cancer medications, chest wall or pulmonary fibro-
sis from radiation treatments, metastasis to the bone which may 
result in fractures or nerve compression, and secondary cancers 
such as leukemia following treatments.13,14,105,106 Furthermore, 
since breast cancer treatments combined with aging increase a 
woman’s risk for cardiovascular disease, it is recommended that 
CRF measures include vital signs monitoring to improve safety 
or uncover abnormal responses to exercise.2,5,14
Finally, since submaximal exercise tests can have large SEM 
and MDD that exceed the MCID, clinicians may wish to recog-
nize that measures of CRF in female breast cancer survivors may 
provide outcomes that over- or underestimate their CRF. Under 
estimating CRF would lead to an ineffective activity prescrip-
tion while overestimating CRF could lead to excessive fatigue, 
discouragement, and disincentive to exercise. Furthermore, over-
estimating the exercise intensity could lead to excessive cardio-
vascular demands and promote arrhythmia, dyspnea, or even 
death.2  Recognizing the limitations of CRF measures, clinicians 
can promote safe and effective exercise training through patient 
education on normal and abnormal exercise responses, informa-
tion on when to contact the physical therapist regarding modifica-
tions to the exercise prescription, or when to contact a physician 
or seek emergent care.
Limitations
The search process was limited to articles written or trans-
lated into the English language; therefore, the search process has 
not been exhaustive. A second limitation was the small number of 
articles found on the validity and reliability of CRF tests in female 
breast cancer survivors.  This lack of evidence prevented substan-
tive and comprehensive evaluations and judgments.  Confidence 
in the findings was also limited by the quality of the reported data 
which has been addressed in detail in prior reviews.9,10 Improved 
reporting will allow for successful future evaluation studies and 
clinical determinations.  
Future Study Recommendations
Recommendations for research on the psychometric prop-
erties of SETs used to assess the CRF in women with breast 
cancer would include the following. First, additional studies are 
required that determine concurrent validity, test-retest reliability, 
and sensitivity to changes in CRF measures following an inter-
vention. Second, cardiorespiratory fitness must be reported as 
oxygen consumption in milliliters per kilogram per minute since 
this measure can be compared over time for a single individual, as 
well as across subjects. Third, SET endpoints need to be clearly 
reported so that readers will know that the study subjects met 
the required test criteria for accurate outcomes. Third, the proper 
statistical analyses need to be used in order to have confidence 
in the findings. The ICC or the COV are the recommended for 
concurrent validity and test-retest reliability; however, the SEM 
and MDD are also necessary to assess clinical relevance.15,44,46 
Fourth, studies on concurrent validity require that comparisons 
be made against gold standard measures as comparisons between 
two non-criterion tests compounds errors. Fifth, to establish 
reasonable precision for test-retest reliability, the recommenda-
tion is to have 50 subjects perform 3 trials each approximately 
2.5 days apart.15,20 Finally, prediction equations that estimate 
CRF, maximal heart rates, and perceived exertion ratings require 
validation within this population.57,58 Ideally, evidence for the 
psychometric properties of SETs would be useful across all stages 
of breast cancer, all types of treatments, and through all survivor-
ship periods.  
CONCLUSION
This study evaluated the psychometric properties, safety, 
and clinical utility of SETs used to determine or estimate CRF in 
breast cancer survivors and provided informed recommendations 
for their use in clinical practice among women with breast cancer. 
However, the evaluation found limited evidence on the psycho-
metric properties of CRF tests for this population. Suggestions 
were made for adapting the current evidence for testing into clini-
cal practice as well as for designing future research on this topic 
among women with breast cancer.
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ABSTRACT
Background: Strength deficits are a common morbidity follow-
ing treatment for prostate cancer.  Accurate assessment of strength 
and muscular endurance following prostate cancer treatments is 
essential to identify deficits and plan rehabilitation. Purpose: To 
identify strength and muscular endurance outcome measures that 
possess strong psychometric properties and are clinically useful 
for examination of men treated for prostate cancer. Methods: 
Multiple electronic databases were searched for articles published 
after 1995. Studies of tools used to assess strength and muscular 
endurance were included if they reported psychometric proper-
ties, were clinically feasible methods, performed on adults, and 
published in the English language. Each outcome measure was 
independently reviewed and rated by two reviewers. A single 
Cancer EDGE Task Force Outcome Measure Rating Form was 
completed for each category of strength or endurance assessment, 
and a recommendation was made using the 4-point Cancer EDGE 
Task Force Rating Scale. Results: Of the original 683 articles 
found, 30 were included in this review. Hand-grip strength and 
hand-held dynamometry were rated 3, recommended for clinical 
use. One repetition maximum was rated 2A, unable to recom-
mend at this time but the measure has been used in research on 
individuals with prostate cancer. Manual muscle testing was rated 
2B, unable to recommend at this time due to lack of psychometric 
support, and muscular endurance testing was not recommended 
(1). Conclusions: Utilizing objective dynamometry for hand 
grip and muscle strength testing provides precise measurement 
to assess baseline status and monitor change among men treated 
for prostate cancer.  
Key Words: prostate neoplasms, muscle performance, dyna-
mometry, outcome measures, psychometrics
INTRODUCTION
Prostate cancer is estimated to be the most common form of 
cancer in American men. After lung cancer, it is the leading cause 
of cancer death among males.1 The American Cancer Society 
estimates that approximately 221,000 new cases of prostate 
cancer will be diagnosed in the year 2015 alone, and approxi-
mately 1 in 7 men will be diagnosed with prostate cancer during 
their lifetime.1 Incidence rates of prostate cancer have changed 
dramatically over the past 20 years; rapidly increasing from 1988 
to 1992, declining sharply from 1992 to 1995, remaining rela-
tively stable from 1995 to 2000, and again decreasing from 2000 
to 2010.1 This unpredictable trend primarily reflects the change 
in the utilization of prostate-specific antigen (PSA) blood testing 
by health care providers for the detection of prostate cancer.1 
Prostate cancer may be a fatal disease, but most men diagnosed 
with prostate cancer do not die from it. The relative United States 
5-year survival rate for all stages of prostate cancer is nearly 
100%, while the 10-year and 15-year survival rates are 99% and 
94%, respectively, with more than 2.9 million men still living.1 
As the number of men living beyond a prostate cancer diag-
nosis rises, focus of care has broadened to include quality of life 
(QOL) issues. Recent research provides evidence that the major-
ity of cancer survivors have significant impairments that often go 
undetected and/or untreated, and therefore may result in disabil-
ity.2 Androgen deprivation therapy (ADT) is a common treatment 
method for the early stages of prostate cancer. During the first 
year of ADT, survivors of prostate cancer (PCS) often experience 
a deficiency in sex hormones, insulin resistance, an increased 
central/visceral adiposity, a decrease in bone density, lean muscle 
mass, and whole body muscle strength.3 What is significant 
for PCS is that the impairments can often be seen in the whole 
body, rather than just the area treated for cancer. Prostate cancer 
survivors receiving ADT had 40% less upper body strength 
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than a group of non-ADT PCS and 22% less upper and lower 
body strength than a healthy control group, and 27% reduction 
in strength compared to a PCS non-ADT group.4 Strength is 
reduced on isotonic testing such as chest press and leg extension, 
isokinetic knee extension testing and isometric testing with grip 
dynamometer.4-7 The long term effects of ADT persist over time 
with a decrease in lean muscle mass.6 Adverse changes in muscle 
composition may exacerbate normal sarcopenia, thereby further 
impacting muscular strength and endurance as well as physical 
function and independent living.  The decrease in muscle mass 
and subsequent strength is associated with impaired functional 
mobility as indicated by increased times to complete a 5 repeti-
tion sit-to-stand test and 6 meter walk test.6,8 
Diminished muscular endurance and fatigue are also increas-
ingly recognized as a troublesome complaint among patients with 
cancer.7,9 Cancer-related fatigue has been hypothesized to be both 
a central phenomenon as well as a peripheral occurrence. Cen-
trally mediated fatigue is thought to arise from the loss of volun-
tary activation of muscles due to processes proximal to the neu-
romuscular junction, while peripheral fatigue has been attributed 
to failure of muscular contraction or metabolic changes within the 
muscle.10 Muscular changes associated with ADT use can influ-
ence muscular endurance in PCS and have a significant negative 
impact on QOL and patients’ self-care abilities. Researchers have 
reported impairments among PCS to be as high as 24% for activi-
ties of daily living (ADLs) and 42% for instrumental activities of 
daily living (IADLS).8 Among such patients, the prevalence of fa-
tigue is generally reported to be greater than 65%.11 Furthermore, 
complaints of diminished endurance and of fatigue persist beyond 
the treatment timeframe.7,12,13
Impairments in strength and muscular endurance have been 
linked to declines in independence, functional mobility, and sub-
sequent QOL. Activities of daily living deficits, the use of an as-
sistive device, and abnormal functional screen findings are asso-
ciated with an increased risk of falling.7 Falls can lead to more 
serious injuries such as an increased risk of fractures and hospital-
izations, thereby decreasing the QOL and level of independence 
for survivors.8 It is important, therefore, to accurately identify im-
pairments in muscular performance in order to initiate early inter-
vention to mitigate the effects of ADT and subsequent functional 
decline among PCS. 
In 2010, the American Physical Therapy Association’s 
(APTA) Oncology Section created the  EDGE (Evaluation 
Database to Guide Effectiveness) Task Force to develop recom-
mendations for outcome measures to be used when assessing the 
status of survivors of cancer.14 This systematic review evaluates 
the ways in which strength and muscular endurance are measured 
clinically in individuals with prostate cancer. The reliability, 
validity, minimal detectable change (MDC), and/or minimally 
clinically important difference (MCID) are important psycho-
metric properties that need to be evaluated to justify clinical use 
of outcome measures.15 Tools used to track and measure patient 
outcomes should be validated in the population in which they are 
used to be most beneficial. Additionally, these tools need to be 
assessed in light of clinical utility, including the availability of 
resources, cost, ease of use, and availability of normative data. 
The purpose of this systematic review is to identify commonly 
used methods of evaluating strength and muscular endurance in 
PCS and to make recommendations of the best methods based on 
psychometric properties and clinical utility.
METHODS
Search strategy
The authors systematically searched the literature for outcome 
measures that directly measured strength and muscular endurance 
to evaluate the psychometric properties and clinical utility of 
such measures.  The primary search was conducted in February 
2014 in PubMed/Medline and CINAHL, with secondary searches 
occurring through July 2014 using Web of Science, Ovid, Google 
Scholar, Sports Discus, Cochrane Review, PEDro, and Academic 
Search Premier.  Search terms used alone and in combination 
included: Prostate cancer or neoplasm and; strength measure/
measurement/test, muscular endurance measure/measurement/
test, manual muscle test, psychometric properties, clinometrics, 
dynamometer/dynamometry, power, and energy, along with 
the following MESH terms: “Muscle strength dynamometer” 
OR “Muscle Strength” OR “Hand Strength.”  Relevant articles 
and journals focusing on orthopedics or fitness measures were 
reviewed recursively for other potential studies. The prostate 
cancer population took first priority within the search, however, 
if no studies included this population, patients with other cancers, 
geriatric patients, and the general population were considered for 
review. 
Included studies of tests of muscle strength and muscular 
endurance had to report psychometric properties, present clini-
cally feasible methods, have adults (preferably male) as partici-
pants, and be published in the English language. The publication 
dates were limited to 1/1/1995 and after, as long as the inclusion 
criteria were met. Studies were excluded if they focused on non-
clinical measures of strength and muscular endurance, or were 
functional mobility measures (eg, Timed Up and Go, sit-to-stand, 
gait speed, etc.).  
After completion of the literature search, relevant articles 
were classified into 4 strength categories and one additional 
category for muscular endurance. The 4 strength categories were: 
manual muscle test (MMT), 1 repetition maximum (1-RM) test-
ing, hand-grip strength (HGS) using dynamometry, and hand-held 
dynamometry (HHD). These categories for strength measurement 
tools were selected based on characteristics of each measurement 
tool described in the available literature. Each outcome measure 
was appraised by two reviewers independently using the Cancer 
EDGE Outcome Measure Rating Form.14 Outcome measures 
were then rated on the 1-4 Cancer EDGE Task Force Rating Scale 
taking into consideration both psychometric properties and clini-
cal utility (Figure 1).14 If an outcome measure rating was found 
to be in disagreement between the two independent reviewers, 
the disagreement was resolved by discussion with all 5 reviewers 
until consensus was obtained. Finally, all articles reviewed for 
an outcome measure were included in a reference section of the 
EDGE form for each appropriate measure.
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4 Highly Recommend Highly recommended; the outcome has good psychometric properties and good clinical utility; the measure has been used in research on individuals with or post prostate cancer.
3 Recommend Recommended; the outcome measure has good psychometric properties and good clinical utility; no published evidence that the measure has been applied to research on individuals with or post prostate cancer.
2A Unable to Recommend at this time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure; 
the measure has been used in research on individuals with or post prostate cancer.
2B Unable to Recommend at this time
Unable to recommend at this time; there is insufficient information to support a recommendation of this outcome measure; 
no published evidence that the measure has been applied to research on individuals with or post prostate cancer.
1 Do Not Recommend Poor psychometrics &/or poor clinical utility (time, equipment, cost, etc.).
Figure 1. Cancer EDGE Rating Scale.
Data Extraction and Synthesis
Relevant psychometric data, when available, were extracted 
and recorded on the Cancer EDGE Task Force Outcome Measure 
Rating Form for each study.  This data included: intra-, inter-, 
and test-retest reliability values, with confidence intervals as 
available, validity, MDC, standard error of measurement (SEM), 
and MCID. Reliability and validity were determined by either the 
Pearson (r) or Intraclass Correlation Coefficient (ICC), or Kappa 
values (K).  Correlation coefficients of greater than 0.75 are 
considered good to excellent, 0.5-0.74 moderate, and below 0.5 
considered poor.16  Kappa values greater than 80% demonstrated 
excellent agreement, 61% to 80% substantial agreement, 41% to 
60% adequate agreement, and less than 40% showed poor agree-
ment.16  Clinical utility was assessed using the criteria of: avail-
ability of resources, cost, ease of use including time necessary to 
complete testing and clinician training, scoring and interpretation, 
and availability of normative data for comparison.
RESULTS
The initial literature search for muscle strength and endur-
ance resulted in 683 articles. The titles were screened and any 
duplicates removed by the assessors.  Article titles and abstracts 
were then reviewed to identify studies that specifically addressed 
the purpose of this review.  Eighty-two articles were retrieved 
and assessed for eligibility. Thirty articles were included in the 
study after exclusions were applied. Figure 2, the PRISMA Flow 
diagram, details the literature search process.
By category, the number of articles reviewed were: MMT 
= 2, 1-RM = 4, HGS = 8, and HHD = 24. No articles were 
found which met inclusion criteria to assess muscular endurance 
measures, although such tests have been used in prostate cancer 
research. Note that some research studies evaluated multiple 
tools, such that the number of articles for each category is not 
mutually exclusive. Table 1 demonstrates the clinical usefulness 
of strength and muscle endurance testing methods. 
Two measures were recommended (rated 3) by the Prostate 
Cancer EDGE Task Force members: HGS and HHD.5 These 
measures are recommended for clinical use to objectify strength 
measures. One repetition maximum testing was scored a 2A, 
unable to recommend at this time, because of a lack of high clini-
cal feasibility, although there is evidence of use in prostate cancer 
research for chest and leg press strength assessment. Manual 
muscle testing and muscle endurance were scored a 2B, unable 
to recommend at this time, due to lack of psychometric support. 
Muscular endurance testing lacks psychometric support and is 
difficult to perform in a clinical setting, and was rated by the Task 
Force as 1, do not recommend. See Table 2 for Task Force ratings 
and clinical utility comments. Table 3 details the psychometric 
properties of the clinical measures of strength.
DISCUSSION
The measurement of strength and muscular endurance in 
men who have been treated with ADT for prostate cancer is 
essential to the rehabilitation continuum. The effect of ADT on 
muscular tissue is well documented,4-6 and the loss of strength 
and muscular endurance impairs functional mobility6 and subse-
quent QOL.4,7 Therefore, valid and reliable measures of strength 
and muscular endurance are critical for this population in order 
to identify deficits, to establish a comprehensive picture of the 
patient’s functional goals and needs, and to monitor progress 
throughout the course of treatment and beyond.
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Findings from this systematic review indicate that the 
measurement of strength is best performed using objective dyna-
mometry for both hand grip and extremity measures. No recom-
mendations for the clinical measurement of muscular endurance 
can be made at this time.
Strength
Accurate measurement of strength using dynamometry is 
achieved through a method that is valid, reliable, and sensi-
tive to change.  Importantly, by quantifying force output as a 
measure of strength, clinicians can measure strength objectively 
to determine deficits, plan treatment, and measure progress. 
Although used widely, MMT, which ranks strength on a 0-5 scale 
(0 representing no muscular contraction and a 5 indicating full 
strength),17 has limitations which need to be considered in light 
of emerging affordable and clinically feasible alternatives which 
provide greater validity and reliability. Manual muscle testing 
is a subjective measure of strength. This is particularly true for 
the antigravity grades of 3 or greater, which lend themselves 
to personal interpretation of the evaluator. Although reliability 
measures indicate that there is adequate intrarater consistency 
within a single evaluator, the amount of force exerted by multiple 
testers of a 3+ for the same participant are quite variable.18 
Another important limitation to be considered is that the MMT 
scale is ordinal rather than interval; the difference between a 
muscle graded a 3 and one graded a 4 is not necessarily the same 
as the difference between a 4 and a 5.  This limitation in grading 
and lack of precision of measurement does not allow the clinician 
to accurately describe strength gains made through rehabilitative 
measures, and generally lacks the sensitivity needed to appreciate 
small gains in strength. 
Tools which are considered accurate possess a small level of 
error. The SEM of the two HHD examined in this review varies 
from 4.9-12.5N.19,20 One kilogram is equivalent to 2.2 pounds or 
9.8N.  With a SEM of no greater than 12.5N, the error of measure-
ment in the HHD is less than 1.3 kg (2.9 pounds). The hand grip 
dynamometers evaluated have a SEM of 0.76 – 1.25 kg.21 Any 
amount of change in strength measures greater than the SEM, 1.3 
kg, is real change. Research and analysis establishing the MDC 
or MCID for dynamometry is slight, but studies reported MDC 
values of 1.75-5.58 kg in cancer populations,20,22 and up to 7.3 kg 
in a healthy population.19 What the actual amount of change in 
force output that is clinically meaningful will vary depending on 
the muscle group tested, the age and gender of the individual, and 
the functional needs of that person.  This clinically meaningful 
change will require the judgment of the clinician.
The validity and reliability of HHD is well established in the 
literature. These psychometric properties have been described for 
multiple populations:  healthy individuals, chronically ill, and 
those with cancer.20,23-27 Overall, validity with strength measured 
using isokinetic dynamometry is good to excellent.25,26 Although 
reliability is reported as good to excellent in most studies,23,24,26,27 
it can be improved through the use of a fixation method. Because 
research shows that the tester gender, body weight, or grip 
strength can influence the force values obtained using HHD,28 
it is important to create a mechanism of consistent resistance. 
Research supports using some external fixation for the dynamom-
eter to improve the interrater reliability of dynamometry in a clin-
ical setting. Studies have investigated different devices including 
brackets,29-31 or straps.32,33 The studies whose psychometric prop-
erties are reported in this review did not use external stabilization, 
and it is reasonable to conclude that reliability measures would 
improve with this use. In a clinical situation, a mobilization belt 
can be strapped around the dynamometer and fixed in opposition 
to the force vector to provide a consistent resistance for maximal 
voluntary contractions. 
Table 1. Clinical Usefulness for Strength and Muscular Endurance Measures
Measure Equipment Needed Cost Ease of Use Scoring/Interpretation Normative Data
MMT No Free High Easy Yes*
1-RM Yes – weights or machines Minimal Moderate Easy Inconsistent
HGS Yes – dynamometer Moderate High Easy Yes
HHD Yes – dynamometer Moderate High Easy Yes
Muscle Endurance Yes – weights or machines Minimal Not established Moderate No
Abbreviations: MMT, manual muscle test; 1- RM, one repetition maximum; HGS, hand-grip strength; HHD, hand-held dynamometry
*Based on the rating of a 5 being “normal” strength.
Table 2. Prostate Cancer EDGE Task Force Ratings and Clinical Utility 
Measure Prostate Cancer EDGE Task Force Rating Clinical Utility
Hand-grip Strength 3 Equipment is easy to use clinically and staff training is simple.  Good clinical utility.
Hand-held Dynamometry 3 Easy to use clinically; methodology similar to manual muscle testing. Normative data available.
1 Repetition Maximum 2A Not often used clinically. Psychometric support is limited.
Manual Muscle Test 2B Highly useful in the clinic, but poor psychometric properties do not support use.
Muscle Endurance 1 Not often tested clinically. Used in research, but lacks psychometric assessment.
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Sensitivity to change is impacted by the tool used, as well 
as the unit of measure for that tool. Manual muscle testing lacks 
properties of measurement which are sensitive. Force is often 
measured by Newtons (N), pounds (lb), or kilograms (kg). The 
unit of force output for MMT remains an ordinal number whereas 
the output on dynamometers is in pounds or kilograms. Muscles 
graded a 4 may have as little as 10% of the maximum strength of 
a muscle.34 Hand-held dynamometry uses a unit of measure that 
is an interval scale; the amount of difference between a 3 and a 
4 is the same as between a 4 and a 5. Sensitivity to change over 
time can then be accurately described.  Furthermore, clinicians 
consistently evaluate patient performance against an expected 
normal level of performance. Use of HHD allows this comparison 
to be made as normative values have been established for human 
strength measures. Although outside the scope of this paper, the 
reader is encouraged to reference the numerous studies reporting 
these values.35-37 
Measurement of strength is most accurate using dynamom-
etry. The use of dynamometry in the prostate cancer population 
is limited to two smaller studies20,22 which used a strain-gauge 
rather than a force gauge typically seen clinically. This limited 
the authors’ ratings of HHD and HGS to a 3 (recommended) 
in this review, however, both HGS and HHD offer the clinician 
a clinically feasible method to measure strength that has the 
necessary psychometric properties to support good validity, 
reliability, MDC, MCID, and sensitivity to change, and have 
been used in other cancer populations. The use of 1-RM cannot 
be recommended secondary to low clinical utility and weaker 
psychometric properties.
Muscular Endurance
Clinically feasible methods of measuring muscular endur-
ance with accompanying sound psychometric properties and 
normative values remain elusive. Because of this, muscular 
endurance, the ability to sustain force output over time, is seldom 
assessed in a clinical setting. Yet understanding overall muscular 
fitness after treatment with ADT is an important consideration 
given the effects of ADT on muscle tissue, including sarcope-
nia.38 A component of muscular fitness is muscular endurance. 
Research is emerging suggesting that muscular endurance is 
lower in men treated for prostate cancer with ADT.7,9 Therefore, 
finding appropriate means to assess this clinically is important for 
monitoring patient status.
The most available method to measure muscular endurance 
is some variation of a repetition to failure loading test. An early 
study examining muscular fitness among men treated with ADT 
compared a group engaged in a resistance exercise program to 
a group without exercise using a fixed load repeatedly lifted at 
a standard rate, and counted the number of repetitions correctly 
completed.7 Findings from this study showed an increase in 
the number of repetitions after 3 months of resistance exercise 
training, with an accompanying decrease in self-reported fatigue 
using the Functional Assessment of Cancer Therapy – Fatigue.7 
Another study recorded the number of repetitions of 70% of 1RM 
lifted until failure comparing a group of men on ADT to a group 
of healthy controls.  This study found no differences between 
groups for muscular endurance repetitions to failure using 70% 
of 1 RM.6 To better understand the implications of these results, 
it is important to examine how muscular endurance should be 
measured.
The American College of Sports Medicine recommends that 
lifting 40-60% of a maximum resistance repeatedly in training 
will increase muscular endurance.39 Intuitively, then, measuring 
endurance should be completed using repetitions to failure of 
40-60% of 1RM.  Neither study purporting to measure muscular 
endurance utilized this method, although findings that an increase 
in repetitions suggest an increase in muscular endurance among 
men using ADT.  The limitation to this study was the lack of 
a healthy control comparison to determine whether deficits in 
muscular endurance were present at baseline.
Measuring muscular endurance with a repetition to failure 
using 40-60% of 1 RM is not without merit.  Establishing a 
baseline measure for an individual is possible, and repeating the 
measure postintervention can inform change. The limitation of 
this methodology is the lack of normative data for age, gender, 
and muscle group.  Such data is difficult to gather, as the number 
of repetitions to failure is largely dependent upon the muscle 
mass of the individual.40
What is needed is a test for muscular endurance which 
possesses good clinical feasibility, along with strong psychomet-
ric properties.  Isokinetic dynamometry offers a more reliable and 
valid method to measure muscular endurance, but lacks clinical 
feasibility.  However, a study of muscular endurance using a 
Biodex stationary dynamometer, measuring maximal voluntary 
isometric contraction (MVIC) levels pre- and post-endurance 
activity, shows promise.41 Findings from this study suggest that 
rather than measuring repetitions to failure as a unit to quantify 
endurance, perhaps measuring MVIC pre- and post-activity may 
provide a more reliable and valid method to measure endurance. 
It may be possible that using HHD to measure MVIC before and 
after some fatiguing activity holds promise for a more clinically 
realistic measure of muscular endurance. At this time, measuring 
muscle endurance clinically is not feasible and this systematic 
review does not support it.
Further investigation is needed in designing a clinically 
feasible, reliable, valid, and standardized method to measure 
muscular endurance. A clinical method of measuring muscle 
endurance should utilize the guiding principles of 40% to 60% of 
maximum resistance lifted over time. The clinical method should 
also be responsive enough to detect differences between healthy 
and injured tissue, as well as have a reliable and quantifiable 
normative unit of measure. 
Other research in cancer outcome measures should focus on 
the specific needs of the population. More studies with men who 
have been treated for prostate cancer examining reliability and va-
lidity as well as responsiveness to change are needed to determine 
intervention effectiveness. Cutoff scores should be established 
to assess the severity of impairment and functional limitations. 
Tools for specific practice settings across the continuum of care 
need to be explored; it is reasonable to believe that responses of 
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individuals will vary based on whether they are in the acute stage 
of recovery or a more long-term stage, as the impact of treatment 
changes with time.
CONCLUSION
Psychometrically strong and clinically feasible outcome 
measures need to be utilized in evidence-based practice of 
physical therapy. Measuring strength and muscular endurance 
precisely in men with prostate cancer allows clinical decision-
making to accurately identify impairments in body structures 
which may impact activity and participation. Both HGS and 
HHD are recommended as valid and reliable methods to assess 
strength in PCS. No clinical measures for muscle endurance 
could be recommended at this time.  Further research is necessary 
to devise a clinically feasible muscular endurance test with sound 
psychometric properties for clinical use in this population.
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ABSTRACT
Background:  Multiple agencies have recognized the increas-
ing care demands and the associated costs of a growing aging 
population with incurable or life-threatening conditions, includ-
ing cancer.  Although the core concepts of physical therapy 
(PT), cancer survivorship and palliative care (PC) appear to 
be congruent and complimentary, there is little evidence in the 
literature demonstrating a consistent role of PT in these settings. 
This article will outline a care philosophy to use for educating 
PTs, patients/clients, interdisciplinary team members, and as a 
guide for PT care for the longitudinal management of the patient 
with a cancer diagnosis, incurable illness, or a life threatening 
illness. Methods: Literature review and perspective regarding 
PT within cancer survivorship, PC and chronic disease manage-
ment in the context of healthcare reform to provide a perspective 
of the PRevention, Intervention, and Sustained wellness Model 
(PRISM) care philosophy. Discussion: The PRISM promotes the 
longitudinal management by the physical therapist for a patient 
with a number of long-term conditions, including cancer survi-
vorship, chronic disease or life threatening illness and its side 
effects.  Prevention includes primary, secondary, and tertiary 
prevention in the presence of a disease.  Intervention is generally 
considered conventional or traditional physical therapy, while 
Sustained wellness incorporates concepts related to maintain-
ing health or slowing the decline of a progressive illness, injury 
prevention, and anticipation and management of potential medi-
cal crises. Conclusion: The PRISM may have utility to guide and 
educate care providers on PT’s role in managing individuals with 
these conditions.  
Key Words: side effects, prevention, navigator, wellness, 
prospective
INTRODUCTION
Palliative care (PC) and physical therapy (PT) are congru-
ent with similar treatment philosophies, including anticipating 
and mitigating predicable and unforeseen medical events, opti-
mizing and maintaining quality of life (QOL) in the existence 
of a disease process or impairment, and supporting the patient 
holistically.1  Despite these similarities, many physical therapists 
(PTs) who work with patients with a chronic disease or a life-
threatening illness are not aware that they are in essence, and in 
reality, providing a component of PC.  Palliative care, while a 
relatively new term to many practitioners, is the holistic, longitu-
dinal management of an individual with a chronic, life threaten-
ing, or incurable illness.2  Cancer survivorship and QOL concepts 
are closely tied to the care philosophy of PC and cancer survivors 
note that QOL is a high priority throughout the survivorship 
journey, of which PT has the potential to play an important role 
across the spectrum of the disease process and treatment of side 
effects.3 For example, chemotherapy treatment is associated with 
pain, fatigue, weakness, and the magnitude of symptoms directly 
affected QOL.4  Rather than focusing on the clinical aspects of 
patient management for the patient with a life threatening illness, 
this critical review of the literature and perspective paper exam-
ines various aspects as it relates to how cancer survivorship and 
PC treatment philosophy are congruent with the overarching 
concepts of health care reform.  This literature review examines 
how PTs and PT practice is best positioned to assist in meeting 
the goals of cancer survivorship and PC through the PRISM care 
model. 
Health care reform and the Affordable Care Act, despite its 
political controversy, brought to light the need for better manage-
ment of life-threatening diseases and chronic illness in the inter-
est of cost-effectiveness and quality outcomes.  Some of the core 
concepts of this management include:
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n		improved access to care, 
n		earlier management, 
n		preparation for medical emergencies and events, 
n		holistic support of the patient and family, and 
n		an integrated care team.  
Reported benefits of this improved management include:
n		the possibility for improved functional capacity, 
n		improved longevity, 
n		reduced medical costs, 
n		reduced stress to patients and caregivers, and 
n			the patient’s active participation in their disease management 
and medical care.5
Despite the congruency and compatibility of the PT and PC 
philosophies, no articles were located that demonstrate strong 
evidence that PT had achieved full integration into care teams 
or were consistently consulted.  This lack of evidence outlines a 
research opportunity to provide evidence for the role of PT within 
PC to best determine where PT principles may be applied with 
the most benefit to the patient, the profession, and to society at 
large.  The purpose of this review is to outline the PRISM care 
philosophy and provide a perspective as to the future role and 
opportunities that the physical therapist is optimally positioned 
to provide. PRISM is a care philosophy and educational tool to 
assist PTs and other stakeholders in understanding PTs role in the 
management of the cancer survivor or the patient with chronic 
disease or life-threatening illness.  This perspective is provided 
in the context of a literature review highlighting issues related 
to the aging population, the disproportionate health care costs of 
this patient population, especially nearing the end of life, and the 
focus on reform of the healthcare system.  These factors provide 
a significant opportunity for PTs to provide resources to manage 
these patients.  
METHODS
The key databases examined in the literature review included 
the APTA’s Open Door portal, PEDro database, CINAHL, and 
Google Scholar from 2003 to 2013. Key terms searched included 
“physical therapy,” “palliative care,” “chronic disease,” and 
“health care reform”/“affordable care act.”  Six articles were 
selected that best outlined the core concepts of the objectives of 
this review.  Although research articles were preferred as well as 
articles published within the past 10 years, the sample of research 
articles providing information related to the topic of PT involve-
ment in PC in the context of healthcare reform were relatively 
limited.  This prompted utilization of some meta-analyses, posi-
tion papers by think-tanks, and expert opinion medical manu-
scripts on the topic, as this level of articles is more common and 
applicable to this review.
RESULTS
In a systematic review by Meier entitled, “Increased Access 
to Palliative Care and Hospice Services: Opportunities to 
Improve Value in Healthcare,” PC services were examined in the 
context of public health policy.6 Meier clarified the definition of 
PC to provide best-possible QOL for patients and family caregiv-
ers, work in an interdisciplinary and community-based fashion to 
promote seamless models of care across a range of settings.  A key 
aspect of PC is that “ideally PC should be initiated concurrently 
with a diagnosis of serious illness and at the same time as curative 
or disease modifying treatments.” A MedPAC report from 2010 
that found that “10 percent—of the sickest Medicare beneficiaries 
accounted for about 57 percent of total program spending, which 
was more than $44,220 per capita per year,” with the costliest 
individuals being those with a chronic disease.6 In a 2010 article 
by the federal Office of Assistant Secretary for Planning and 
Evaluation, individuals with a life-threatening illness or chronic 
disease and their associated conditions and functional impairment 
constitute about 10% of all patients in the United States (US), 
but account for well over half of the nation’s health care costs.6 
Meier found 15 articles that provided evidence that PC programs 
positively affected “physical and psychosocial symptoms, family 
caregiver well-being, bereavement outcomes, and patient, family, 
and physician satisfaction.” A few studies noted that PC treatment 
philosophies may even be associated with a prolongation of life. 
Meier highlighted an article by Morrison et al in 2008 describ-
ing a net per-patient savings of $2,659. Common barriers to PC 
include variable access, inconsistent services (especially in rural 
areas), and an inadequate workforce with expertise in PC.6 
In a white paper outlined by the RAND Corporation entitled, 
“Living Well at the End of Life,” Lynn and Adamson discussed 
the issue of aging baby boomers, which will significantly add 
to the demand upon healthcare resources.7 By the year 2030, 9 
million Americans who were born in the 1950s will be reaching 
85 years of age and are likely to face significant disability.7 When 
living with a life-threatening illness, a disproportionate amount of 
health care costs are concentrated in the last several weeks and 
months of life. Nine out of 10 people who die have a chronic life-
threatening illness including cancer, cardiac, respiratory illness, 
dementia, and stroke. About 25% of those with chronic illness 
may experience disability from their condition at any one time. 
Three different common scenarios of chronic, life-threatening 
illness were outlined:
1.   “Short period of evident decline” which is typical of cancer. 
In this case, there is a longer term preservation of comfort 
and function until the disease process becomes overwhelming 
to the systems, then a steady, rapid decline in function may 
occur.
2.   “Longer term limitations with intermittent exacerbations and 
sudden dying.” This is more common with organ system 
failure pathologies such as COPD and CHF.
3.   “Prolonged dwindling.” This is more typical of central 
nervous system failure that is generally of a slow decline 
where institutional long-term care facilities are beneficial. 
Based on these descriptions, methods to innovate and reform 
care for these chronically ill adults were recommended, including 
integrating care across settings, quality improvement programs for 
Rehabilitation Oncology
Vol. 33, No. 2, 2015
47
pain management, advanced directive planning, and PC consulta-
tions.  Some longer term suggestions by the RAND Corporation 
include addressing the shortage of caregivers, reforming federal 
finance policy, evaluating the cost-effectiveness of treatments, 
re-evaluating life possibilities for dementia (having the person 
make life choices before decisional capacity is absent), and an 
emphasis on strategic planning.  These recommendations help lay 
the framework for what gaps PTs may fill in the realm of PC and 
chronic disease management.  
The Agency on Healthcare Research and Quality (AHRQ) 
performed a meta-analysis entitled, “Palliative Care for Adults”, 
to analyze the evidence related to practice recommendations and 
clinical guidelines for PC practitioners.8 The quality of evidence 
and strength of recommendations were categorized to provide 
the reader with improved information to provide evidence-based 
best practices in PC.  Some of the highlights of the findings 
included that planning for PC should begin relatively soon after 
diagnosis of a life-threatening illness. Emphasis was on the phys-
ical symptoms of a disease causing suffering and that control-
ling these symptoms should be a priority of PC practitioners. 
Communication with patients and families was a critical compo-
nent to set realistic goals, but provide realistic hope. The authors 
provided additional evidence that PC was compatible, and not 
mutually exclusive, with all other medical treatments, including 
curative measures. Even after the patient’s death, the healthcare 
team plays a key role in the grief and bereavement process. When 
discussing which patients would be appropriate candidates for 
PC, considerations include disease progression with functional 
decline, pain or symptoms not responding to treatment, and a 
need for advance care planning.  Functional decline and pain 
control are two categories of interventions that PTs may be able to 
assist in the management of. The AHRQ document listed several 
diagnoses that may prompt PC consideration including “debil-
ity/failure to thrive, cancer, heart disease, pulmonary disease, 
dementia, liver disease, renal disease, and neurologic diseases 
such as stroke, Parkinson’s, amyotrophic lateral sclerosis (ALS), 
and multiple sclerosis (MS).”  Several neuromuscular, musculo-
skeletal, cardiopulmonary, and neoplastic conditions are within 
the scope of PTs practice.  
An important component to determine the needs of the 
individual with PC or with a life-threatening illness is the 
ability to quantify and predict the level of disability, extent of 
disease, and possibility of death.  An article by Lau et al entitled, 
“Use of Palliative Performance Scale (PPS) for End-of-Life 
Prognostication in a Palliative Medicine Consultation Service” 
was a prospective analysis of 513 patients evaluated by a British 
Columbia PC team.9 The PPS as described by Wilner and Arnold 
evaluates 5 observer-related domains to rate a patient in vari-
ous categories to attempt to describe the level of disease and to 
identify and track potential care needs of PC patients.10 The 5 
categories included:
n		Ambulation;
n		Activity level;
n		Evidence of disease; 
n		Self-care, intake; and 
n		Level of consciousness.  
Besides the evidence of disease component, all components 
are consistently evaluated by PTs as a regular part of their scope 
of practice. Lau et al report that initial PPS scoring is a significant 
predictor of survival, challenges are present due to the “ambigu-
ity and difficulty when assessing patients at higher PPS because 
of the subjective nature of the tool.”9  This tool and its potential 
usefulness in predicting survival rates may be useful to PTs who 
are working with individuals facing life-threatening illness in 
various stages of disease progression. This may provide PTs with 
improved data on anticipated lifespan and may assist in improved 
activity prescription and anticipatory equipment prescription for 
future disease progression.
When shifting focus more specifically toward PT involve-
ment within PC, a key finding in a manuscript based on expert 
opinions was that “Rehabilitative services are underutilized in the 
PC setting, and more research is needed to address how patients 
may benefit as they approach the end of their lives.”11 The role 
of rehabilitation in PC is described and the evidence for the 
benefit of rehabilitation for several major diagnoses reviewed. 
With regard to PT, 3 facets of PT in PC were outlined:  (1) Direct 
patient care, (2) Educating the patient, family, and caregivers, and 
(3) Functioning as a team member within the interdisciplinary 
group.  In addition to the physical benefits provided, the authors 
discussed the psychological benefit of PT, including several cita-
tions providing evidence for a reduction of psychological suffer-
ing when participating in rehabilitation in patients with terminal 
cancer.  In later stages of disease progression, this reduction 
in psychological distress and suffering may outweigh physical 
gains and pain reduction that the PTs may be intending to treat. 
Specific disease conditions and the clinical indications for treat-
ment were described including ALS, advanced dementia, chronic 
heart failure, COPD, and outlined specific treatment regimens. 
Some limitations to rehabilitation and PC described included 
infrastructure of the medical system not supporting the utiliza-
tion or cost-effectiveness of PT within PC. In addition, func-
tional outcome measures were advocated, such as the Palliative 
Performance Scale.10  
Palliative Care and Management Principles in Older 
Patients with Advanced Chronic Obstructive Pulmonary Disease, 
a systematic review by Yohannes, a physiotherapist in the 
United Kingdom examined the care principles for end stage 
COPD.12 Psychiatric disorders, in addition to dyspnea from the 
disease process, are a significant issue. With regard to dyspnea 
management for this patient population, as expected, this was 
a key symptom that required management and reported as 90% 
prevalence of dyspnea at rest or minimal exertion with end stage 
COPD as compared to end stage CHF with 60%.12 Application of 
a fan pointed in the direction of the face displayed early evidence 
of reducing the symptoms of dyspnea, in addition to commonly 
utilized medical treatments including supplemental oxygen and 
medications.  Fatigue was a common symptom noted by nearly 
all patients. Yohannes recommended applying a fatigue rating 
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scale such as the Manchester COPD Fatigue Scale. This scale is 
valid and reliable in quantifying fatigue.  Pulmonary rehabilita-
tion displayed evidence of reducing and controlling fatigue in this 
patient population.12 Specifically, home-based physical rehabili-
tation was useful in maintaining physical functioning in advanced 
COPD.  Finally, unlike late stage cancer, patients with COPD are 
less likely to have access to or be aware of PC services, creating 
a health disparity in this underserved population.12
PRevention, Intervention, Sustained wellness Model (PRISM) 
Care Philosophy
The PRISM care philosophy encapsulates and summarizes 
multiple concepts of chronic disease management. The inten-
tion of the PRISM care philosophy is to provide an educational 
tool and guiding care philosophy toward care of the patient 
with a chronic disease or life-threatening illness (Figure 1). The 
PRISM may be employed to increase the awareness, understand-
ing, and communication of the varied roles that PTs offer in the 
management of the cancer survivor or patient with a chronic or 
life-threatening disease.  The visual representation of a spectrum 
provides illustration of the relative continuum of roles that PT is 
able to offer, as opposed to a dichotomous perspective of “PT or 
no PT.” This spectrum provides for an illustration of a variety of 
different involvement levels for the physical therapist from an 
annual check-up with a PT in the early stages of a newly-diag-
nosed disease through early intervention for an impairment or 
functional imitation, all the way through providing psychosocial 
support and comfort measures at the transition to hospice care. 
To illustrate the clinical applicability and utility of the PRISM 
care philosophy, the 3 core concepts of Prevention, Intervention, 
and Sustained wellness are summarized with patient examples. 
These examples are not meant to be all-inclusive, only to high-
light common opportunities that PTs may apply each phase of the 
PRISM care philosophy. 
Prevention.  Preventative care, a growing area of physical 
therapist practice, is not commonly considered in the presence 
of an already diagnosed incurable illness. Physical therapist care 
in the realm of prevention may take multiple forms in chronic 
disease. A common consideration of primary prevention is the 
initial education in avoiding at-risk behaviors, such as poor diet 
or smoking, or encouraging disease-preventing behaviors, such 
as exercise and advocating for appropriate cancer screenings. 
In conditions such as COPD and CHF, a periodic or annual 
re-evaluation and exercise or activity prescription may be 
appropriate to maintain strength and functional capacity. These 
periodic re-evaluations (prospective surveillance) may be able 
to establish baseline functional levels and identify an early exac-
erbation of a disease process and prompt further management as 
appropriation. Prevention in an acute or in-patient setting may 
include prospective screenings by PTs of all patients within a 
specific nursing unit to provide early identification and treatment 
of potential rehabilitation needs before several days of bedrest 
causes unwanted medical sequelae.
Intervention. The intervention phase of the PRISM philoso-
phy is what is commonly considered by interdisciplinary team 
members, patients, and some PTs as traditional or conventional 
PT. Although this is what is commonly known as PT, there is 
perceived to be an underutilization of traditional PT services in 
the presence of a cancer diagnosis, chronic disease, or other life-
threatening illness. A portion of this underutilization may be the 
perception that in order for traditional PT to meet the tenets of 
medical necessity, reasonable progress must be made. As many 
chronic or life-threatening illnesses require the skill of a physical 
therapist to maintain or slow the decline of function or impair-
ments, conventional intervention-based PT may be indicated. 
This point was clarified in the US Supreme Court case Jimmo 
vs Sebelius that ruled rehabilitation services may be applicable 
and medically necessary to maintain or slow the decline of the 
functional status of a patient with a degenerative illness or an 
incurable condition.13 This may include concepts such as cancer 
rehabilitation or impairment-based interventions for side effects 
of treatments or surgical procedures.  This may also include 
intervention-based treatments for conditions such as pelvic floor 
rehabilitation for genitourinary cancers.
Sustained wellness.  The last concept entails the relatively 
stable period after an exacerbation or a change in an incurable 
or chronic condition where a certain level of activity, exercise, 
or health maintenance behaviors are required or beneficial to 
maintain an optimal level of activity and participation and allow 
the patient/client to enjoy the highest level of QOL for as long of 
a duration as possible. In the absence of these Sustained wellness 
activities, a patient’s condition may worsen; however, within the 
Sustained wellness phase, skilled PT may not be medically neces-
sary, feasible, or appropriate. An example of this is a facilitated 
exercise regimen provided by an exercise and wellness program 
for cancer survivors in active treatment and who prefer supervi-
sion, guidance, or encouragement with a prescribed exercise 
regimen. This may include a cancer survivor who has achieved 
remission or cure but is still working through after effects of 
chemotherapy, radiation, or surgical intervention, or an “after-
care” program for patients with residual deficits after a stroke 
to maintain a certain level of functioning when their recovery 
has stabilized and their care no longer meets medical necessity 
for physical therapist services. These after-care programs may 
begin with an exercise prescription for a certain level of activity 
from a physical therapist and facilitated by a healthcare or exer-Figure 1. PRISM visual depiction.
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cise professional with training in the medical condition and the 
complexities of the condition. In the Sustained wellness phase, 
the physical therapist may provide a consultative or supportive 
role with periodic re-evaluations to monitor, correct, or progress 
an exercise prescription. 
DISCUSSION
Based on the literature review, the PRISM care philosophy 
and the philosophical compatibility with cancer survivorship 
and PC, several key outcomes should be pursued to assist in PTs 
managing the patient with a cancer diagnosis, chronic disease, 
or life-threatening illness. These are discussed in the context of 
the APTA’s Position Statement passed by the House of Delegates 
in 2011 entitled THE ROLE OF PHYSICAL THERAPY IN 
HOSPICE AND PALLIATIVE CARE HOD P06-11-14-11.14 
“Resolved, The American Physical Therapy Association 
(APTA) endorses the inclusion of the following concepts in 
hospice and PC:
n			Continuity of care and the active, compassionate role of PTs 
and physical therapist assistants in hospice and PC.
n			Respect for the rights of all individuals to have appropriate 
and adequate access to physical therapy services, regardless 
of medical prognosis or setting.
n			An interdisciplinary approach, including timely and 
appropriate physical therapist and physical therapist assistant 
involvement, especially during transitions of care or during a 
physical or medical change in status.
n			Education of PTs, physical therapist assistants, and respective 
students in the concepts related to treating an individual while 
in hospice and PC.
n			Appropriate and comparable coverage and payment for 
physical therapy services for individuals who have transitioned 
to hospice or PC in all clinical settings.”
Each component of this position is examined as to the PT 
profession’s capacity, opportunities, and limitations in achieving 
each of these tenets.
Continuity of care and the active, compassionate role of PTs 
and physical therapist assistants in hospice and PC.
In this tenet, an emphasis is placed on the continuity of 
care with the PTs.  Currently PTs and PTAs are well-educated 
in compassionate care in a more episodic manner of care with a 
clear “evaluation” and “discharge” with the hope of a successful 
discharge to where the physical therapist will deem a treatment 
session “successful” when the patient does not have to return to 
the care of the physical therapist. Although this thought process 
is changing, it is changing in a slow manner and is incompatible 
with the care concepts of PRISM and chronic disease manage-
ment.  The management of the individual with a life-threatening 
illness and chronic disease requires a more longitudinal manage-
ment of patient care that may require periodic re-assessment, 
early identification of disease progression, anticipation of crisis 
events or medical exacerbation, and some periods of conven-
tional intervention-based PT management.  The APTA endorses 
positions that highlight this model of care, including endorse-
ment of an Annual Visit with a Physical Therapist and Physical 
Therapist of Record and “Hand Off” Communication.15,16 These 
positions provide examples of the PRISM concepts of prevention, 
early identification, and continuity of services. It is recommended 
that future professional education incorporate these concepts 
into curricula. A suggested emerging role of a physical therapist 
is that of a “rehabilitation navigator,” with analogous structures 
to an attending physician or nurse navigator. This rehabilitation 
navigator would coordinate care of a variety of rehabilitation 
professionals throughout the disease process and maintain a 
long-term relationship with the patient. In addition to providing 
components of disease-specific treatment, the navigator would 
assist in symptom monitoring as well as facilitation and consulta-
tion of specialist PTs who focus in one area of specialty, while 
the therapist navigator provides for longitudinal management and 
coordination of care throughout the disease continuum.
Respect for the rights of all individuals to have appropriate 
and adequate access to physical therapy services, regardless of 
medical prognosis or setting. 
This objective of the APTA’s position on the role of PT in 
hospice and PC focuses on both ends of the disease spectrum, 
touching on the awareness and referral process requirements 
among all stakeholders as to the PTs role in management in 
Prevention, early Intervention, and Sustained wellness across the 
continuum of care.17,18  Some patients may not understand the role 
of exercise, prevention, wellness behaviors, and early intervention 
that a physical therapist may offer, especially in the presence of 
chronic or life-threatening illness. The health care team members 
who are commonly considered referral sources for PTs, includ-
ing physicians, mid-level providers, nurse navigators, and social 
workers, may not have increased awareness of the role of PT in 
the continuity of care beyond conventional PT care.  Historically, 
the APTA has endorsed improving access to PT services through 
legislative efforts including direct consumer access, especially as 
it relates to wellness services.  As an example, Michigan was the 
most recent, and 50th state in the US, to obtain direct consumer 
access effective January 2015. The legislative rules did place a 
time limitation on conventional PT visits, but no visit limits on 
wellness or preventative visits to the PT services.19  
An interdisciplinary approach, including timely and appropri-
ate physical therapist and physical therapist assistant involve-
ment, especially during transitions of care or during a physical 
or medical change in status. 
In an unpublished doctoral dissertation by Wilson entitled, 
“Perceptions of PTs Regarding the Role of Physical Therapy 
Within Hospice and Palliative Care in the USA and Canada: A 
Qualitative Study”, a common theme noted by the participants 
in the study was the importance of integration into the care team 
to provide an interdisciplinary approach to patient management. 
There was wide variability and frequent inconsistencies to physi-
cal therapist involvement into the Interdisciplinary Team (IDT)/
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Interdisciplinary Group (IDG). This emphasizes the importance 
of continuity of services and hand-off of care described in the 
APTA position when a patient transfers form one setting to 
another and that the physical therapist of record should provide a 
comprehensive description of the overall care philosophy of the 
patient, recommendations for provision of treatment, precautions, 
contraindications, and individual patient preferences.16 Several 
examples of this hand-off of care includes transition to and from 
home into hospitalization, discharge from sub-acute rehabilita-
tion or in-patient rehabilitation into the home setting, and transi-
tion from outpatient therapy to a cancer survivorship exercise 
program to wellness or monitoring settings, to name a few. 
Education of PTs, physical therapist assistants, and respective 
students in the concepts related to treating an individual while 
in hospice and palliative care. 
In promoting and proliferating the PRISM role of PT within 
cancer survivorship, PC and chronic disease management, empha-
sis is placed on the potential circumstances that PTs and PTAs 
may be self-limiting their own involvement in cancer survivor-
ship, chronic disease management, and PC services. The authors’ 
clinical observations note that PTs and PTAs lacked awareness 
of their role or potential role in the longitudinal management of 
a cancer survivor or the patient with a chronic or life-threatening 
illness. This lack of understanding of the role of PT within cancer 
survivorship or PC among PTs and PTAs may cause hesitation 
among referring physicians or practitioners, even those who are 
strong advocates of the role of rehabilitation professionals in 
management of their patients. The evidence of PT within cancer 
survivorship and PC is continuing to grow; however, a slow tran-
sition is expected toward educating PT/PTAs in this role as much 
of the institutional practice changes have historically occurred 
through professional education as opposed to post-professional 
education. Although forward-thinking programs may be adopting 
cancer survivorship, chronic disease management, and PC prin-
ciples into curricula, it may take an external credentialing body 
like CAPTE (Commission on Accreditation of Physical Therapy 
Education) to successfully drive more widespread change.
Appropriate and comparable coverage and payment for physi-
cal therapy services for individuals who have transitioned to 
hospice or PC in all clinical settings.
Another administrative barrier to this care setting is that 
current payment structures that do not consistently pay for PT 
services in direct access, self-referral environments, or near the 
end of life. The Medicare Hospice per diem rate is noted as a 
potential limiting factor in PT provision in the end of life care. 
One added benefit of PC services that creates significant practice 
opportunities for PTs, is most insurances cover PC services in 
the same payment structure that they cover traditional PT care. 
The APTA is creating an Alternative Payment System work-
ing with the American Medical Association and the American 
Occupational Therapy Association to update the PT CPT codes.20 
This new billing, coding, and payment model better positions the 
PT profession to provide an improved spectrum of care, especially 
in the interest of wellness and prevention models to better capture 
the skills of PT in the context of PRISM.  This important step to 
improve support and access to PT includes properly reflecting 
the decision making capacity of PT as a consultative service as 
compared to a time-based, intervention-oriented service.
CONCLUSION
The PRISM philosophy incorporates several professional PT 
positions and encapsulates current evidence on cancer survivor-
ship, management of chronic conditions, and longitudinal care of 
terminal or life-threatening illness and may have utility to guide 
and educate care providers on PTs role in managing individuals 
with these conditions. These core concepts are visualized in the 
PRISM care philosophy and are outlined in the APTA’s position 
on hospice and PC are not just localized to patients within PC 
or even those with a chronic disease or a life-threatening illness. 
These concepts are a philosophical evolution of the profession 
of PT from an episodic, intervention-based practice, toward a 
primary care service that incorporates all aspects of participation 
in life events across the entire spectrum with a focus on QOL. To 
achieve these lofty goals, the physical therapist and profession 
must advocate for appropriate policy, education, and payment 
structures for PTs of the future to manage these individuals in a 
longitudinal manner.
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